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1. ABBREVIATIONS 
 
 
ADC  Apparent diffusion coefficient 
5-ARI  5-alpha reductase inhibitor 
AS  Active surveillance 
ATFS  Active treatment-free survival 
AUA  The American Urological Association 
BPH  Benign prostatic hyperplasia 
BT  Brachytherapy 
CaPSURE The Cancer of the Prostate Strategic Urological Research Endeavor 
CSAP  Cryosurgical ablation of the prostate 
cT  Clinical T –class 
CT  Computed tomography 
cTNM  Clinical Tumor-Node-Metastasis-stage 
DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging 
3D-CRT Three-dimensional conformal radiation therapy 
DRE  Digital rectal examination 
DW-MRI Diffusion-weighted magnetic resonance imaging 
EAU  The European Association of Urology 
EBRT  External beam radiation therapy 
ER  Emotional role  
ERSPC The European Randomized Study of Screening for Prostate Cancer 
%fPSA Free/total PSA ratio 
FPXI  The FinnProstate Study XI 
HDR-BT High-dose rate brachytherapy 
HGPIN High-grade prostatic intraepithelial neoplasia 
HIFU  High-intensity focused ultrasound 
HRQL  Health-related quality of life 
IGRT  Image-guided radiotherapy 
IIEF-5  The International Index of Erectile Function 
IMRT  Intensity-modulated external-beam radiotherapy 
IPSS  The International Prostate Symptom Score 
ISUP  International Society of Urological Pathology 
LDR-BT Low-dose rate brachytherapy 
LHRH  Luteinizing hormone-releasing hormone 
MRI  Magnetic resonance imaging 
mRNA  Messenger ribonucleic acid 
MRSI  Magnetic resonance spectroscopy imaging 
PASS  The Prostate Active Surveillance Study 
PC  Prostate cancer 
PCA3  Prostate cancer antigen 3 
PCPT  The Prostate Cancer Prevention Trial 
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PET  Positron emission tomography 
PIVOT The Prostate Cancer Intervention Versus Observation Trial 
PLCO  The Prostate, Lung, Colorectal and Ovarian cancer screening trial 
PR  Physical role 
PRIAS The Prostate Cancer Research International: Active Surveillance 
Study  
ProtecT The Prostate testing for cancer and Treatment trial 
PSA  Prostate-specific antigen 
PSAD  PSA density 
PSADT PSA doubling time 
PSAV  PSA velocity 
pTNM  Pathological Tumor-Node-Metastasis-stage 
QALY  Quality-adjusted life year  
QOL  Quality of life 
RARP  Robot-assisted radical prostatectomy 
REDEEM The Reduction by Dutasteride of Clinical Progression Events in 
Expectant Management trial 
REDUCE The Reduction by Dutasteride of Prostate Cancer Events trial 
RP  Radical prostatectomy 
SEER   Surveillance, Epidemiology, and End Results program 
SPCG-4 The Scandinavian Prostate Cancer Group Study Number 4 
STUMP Stromal tumour of uncertain malignant potential 
TNM-stage Tumor-Node-Metastasis-stage 
TRUS  Transrectal ultrasound 
TURP  Transurethral resection of prostate 
WHO  World Health Organization 
WW  Watchful waiting 	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3. ABSTRACT 
 
Prostate cancer (PC) is a significant health problem worldwide. It is the second most 
frequently diagnosed cancer and the sixth leading cause of cancer death among men. 
The wide use of prostate-specific antigen (PSA) has led to increased detection of 
PCs in its early stages. Active surveillance (AS) has emerged as an alternative 
management option to that of immediate radical treatments of these potentially 
overdiagnosed PCs. The aim of AS is to avoid or at least delay the side effects of 
immediate treatments. 
 The objective of this study was to evaluate the feasibility of AS as a 
management option for low-risk PC and determine how AS affects the quality of life 
(QOL) of low-risk PC patients. The more specific aims of the present study were to 
evaluate the short-term outcomes of the prospective AS cohort, analyse the effects of 
AS on the QOL during screening and AS overall, assess the respective roles of 
diffusion-weighted magnetic resonance imaging (DW-MRI) and a free/total PSA 
ratio as diagnostic and prognostic tools in AS. 
 The PRIAS (Prostate cancer Research International: Active Surveillance) 
study is an international prospective AS trial that originates from the European 
Randomized Study of Screening for Prostate Cancer (ERSPC). ERSPC is a 
multicenter, population-based and randomized screening trial that is being conducted 
in eight European countries. In study I, the outcomes of the 500 first PRIAS patients 
were analysed, the main outcome parameter was active treatment-free survival. 
Secondary endpoints included reasons for discontinuing AS, findings in the standard 
1-year rebiopsies, and outcomes after radical prostatectomy. For the health-related 
quality of life (HRQL) analyses, the Finnish version of the RAND 36-Item Health 
Survey was used in both QOL studies. In addition, participants also received IPSS 
and IIEF-5 questionnaires in study II to analyse possible voiding symptoms and 
erectile function. In study III, RAND-36 QOL questionnaires were delivered to a 
total of more than 2000 screening participants of the Finnish arm of the ERSPC trial 
in five phases of the first screening round. In study IV, 80 men who had enrolled in 
the Finnish arm of the PRIAS study underwent DW-MRI before standard 1-year 
rebiopsy. In study V, the global PRIAS study cohort was used with the initial free 
PSA value available in 939 patients to assess the role of free/total PSA ratio 
(%fPSA) as a prognostic tool in AS. 
 Strict AS criteria of the PRIAS protocol resulted in a quarter of the patients 
stopping surveillance within two years after PC diagnosis. The main reason for 
discontinuation was adverse findings in the standard 1-year rebiopsy. Biopsy results 
were independent of the PSA-doubling time (PSADT). AS did not provoke major 
short-term QOL changes as assessed by standardized questionnaires and none of the 
patients on AS discontinued due to anxiety or distress. The HRQL of study patients 
was even better than that for the general age-stratified Finnish male population. 
Moreover, the PC screening did not have substantial effects on the short-term QOL 
of participants. This study population also had similar or slightly higher HRQL 
scores compared to the reference values obtained from the age-stratified general 
Finnish male population. DW-MRI, as interpreted in a routine clinical setting and 
performed in this study, could not predict treatment change or adverse rebiopsy or 
radical prostatectomy findings. PCs were small and rather well-differentiated, 
making it challenging to visualize these tumours using MRI. Free/total PSA ratio 
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(%fPSA) at diagnosis could not predict outcomes of AS, although median %fPSA 
values were significantly lower in patients with treatment change after one year of 
surveillance. However, %fPSA kinetics may predict future treatments. 
AS is a feasible management option for patients with low-risk PC. Short-
term analyses revealed that a quarter of men discontinue AS, mainly because of 
reclassification of PC in standard rebiopsy, which highlights the importance of 
accurate diagnostics. Neither screening nor AS seemed to provoke short-term 
disturbances in QOL in the PC continuum. Small low-grade PCs are a challenge for 
non-spezialized radiologists to visualize accurately by DW-MRI. Change of %fPSA 
over time may have a value as a prognostic tool in AS. 
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4. INTRODUCTION 
 
 
Prostate cancer (PC) is currently the most common malignancy in males in Finland 
and other Western countries (Jemal et al. 2011; Pukkala and Rautalahti 2013). The 
number of new cases reported has increased dramatically in recent years, which is 
mainly due to active and widespread use of prostate-specific antigen (PSA) in the 
diagnosis of PC. It has been estimated that up to half of all PCs, detected by PSA 
testing are clinically insignificant, which indicates that even if PC was not 
diagnosed, these tumours would not cause any symptoms during the men’s lifetimes 
(Draisma et al. 2003). The detection of clinically insignificant cancers leads to 
substantial overdiagnosis of PCs and overtreatment of patients. Overtreated patients 
are unnecessarily exposed to the side effects of radical treatments that provide no 
survival benefit but which may have an unfavourable effect on quality of life (QOL). 
Active surveillance (AS) has emerged as an alternative strategy for managing these 
potentially overdiagnosed PCs. The idea of AS is to initially withhold radical 
treatments (i.e. surgery or radiation therapy), but reserve the opportunity for deferred 
treatment with curative intent in the case of disease progression or reclassification 
during follow-up.  
AS takes advantage of the long natural history of PC and the good prognosis 
associated with localized low-grade disease. AS strategy is based on defined triggers 
to detect and predict higher risk PC in patients during follow-up. Currently 
diagnostic PSA, Gleason score at prostate biopsy and Tumor-Node-Metastasis-stage 
(TNM-stage) have been widely studied and they have established their position as 
significant prognostic factors for PC. During follow-up, patients are closely 
monitored using tools such as PSA, clinical examinations such as digital rectal 
examination (DRE) and prostate rebiopsies, and when any signs of disease 
progression occur, deferred radical treatment is given (Parker et al. 2004).  
Hitherto, data related to AS are scarce and outcome of long-term follow-up is 
lacking. In addition, prospective and randomized trials, in which AS is compared 
with immediate radical treatment have not been published. The present research 
project investigates the feasibility of AS as a management option for low-risk PC 
within the framework of the PRIAS (Prostate cancer Research International: Active 
Surveillance) study (van den Bergh et al. 2007). The PRIAS- trial is an international 
prospective AS- trial that originates from the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) (Schröder et al. 2003). The PRIAS study 
was initiated in 2006 in the Erasmus University Medical Center in the Netherlands 
and it is still ongoing. PRIAS is currently the largest prospective AS study in 
existence. The study design of this prospective cohort study does not include 
randomization, since the differences in survival benefits between immediate radical 
treatments and AS would probably appear minor and a large patient cohort in 
addition to long follow-up would be needed, thus making such a study difficult to 
conduct.  
The objectives for study of this thesis were to investigate the feasibility of 
AS as an expectant management strategy for low-risk PC and to analyse outcomes of 
follow-up on short-term after PC diagnosis. The specific aim was also to analyse the 
QOL during the screening and the subsequent AS after the diagnosis of low-risk PC. 
One of the main challenges to using the AS approach is to find those cancers that 
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progress and offer these patients a curative treatment in time. A substantial part of 
this thesis was to clarify the role of magnetic-resonance imaging (MRI) and 
free/total PSA ratio (%fPSA) as possible additional prognostic tools for AS. 
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5. REVIEW OF LITERATURE  	  
5.1 The Prostate 
 
The prostate is a walnut-sized exocrine gland and a part of the male reproductive 
system.  It is located in the pelvis, just below the bladder, anterior to the rectum and 
it surrounds the proximal urethra. The prostate can be divided into central, peripheral 
and transition zones (Fig.1). The transition zone is the common area for benign 
prostatic hyperplasia and a peripheral zone for PC. Approximately two thirds of the 
prostate consist of glandular tissue and one third of fibromuscular tissue. The main 
function of this gland is the excretion of fluid that forms one-fifth the volume of the 
semen ejaculate. This prostatic fluid helps to carry and nourish the sperm. The 
smooth muscles of the prostate have an essential role in controlling the flow of 
semen during ejaculation. PC is a malignant disease of the prostate, but several 
benign conditions, such as benign prostatic hyperplasia and prostatitis commonly 
and coincidently occur in the prostate (Campbell-Walsh Urology 2007). 
 
 
 
  	  
Figure 1. The prostate gland divided into zones. 	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5.2 Epidemiology 	  
 
Prostate cancer (PC) is a significant health problem worldwide. PC is the second 
most frequently diagnosed cancer and the sixth leading cause of cancer death among 
men worldwide with an estimated 903 500 new diagnoses and 258 400 deaths in 
2008, this represents 14% of all new cancer cases and 6% of all cancer deaths in 
males (Jemal et al. 2011). The incidence rates of PC vary by more than 25-fold 
worldwide. Elderly men are more often affected by PC, which makes the disease a 
considerable health problem in developed countries. Thus, the highest estimated PC 
incidence rates (age standardized rate per 100 000, in 2008) are observed in the 
highest resourced areas of the world, in North America (85.6), Australia/New 
Zealand (104.2), Western Europe (93.1), Northern Europe (73.1), and the lowest in 
South-Central Asia (4.1). 72% of the PC cases and 53% of the PC deaths occur in 
developed countries (all regions of Europe, North America, Australia/New Zealand, 
and Japan), which have <20% of the world population (Center et al. 2012). 
However, the highest estimated PC mortality rates are seen elsewhere, primarily in 
the Islands of the Caribbean (26.3/100 000), and in Southern Africa (19.3/100 000). 
The lowest mortality rates are found in Eastern Asia (2.5/100 000) (Ferlay et al. 
2010).  
Between the mid-1980s and early 1990s, after the introduction of the PSA test, 
PC incidence rates increased in many high-income countries (Potosky et al. 1995; 
Etzioni et al. 2002; Baade et al. 2009; Bray et al. 2010). Although there is still no 
clear declining incidence trends in sight, most of the registries in developed 
countries have shown signs of a stabilization (Center et al. 2012). In contrast to the 
increasing incidence of PC, the PC mortality rates have decreased in many high-
income areas (North America, Oceania, Northern and Western Europe)(Center et al. 
2012). In the United States this decrease has been particularly noticeable and over 
the last decade the mortality rates have decreased by as much as 4.3% (9.9/100 000) 
in 2008 (Jemal et al. 2010). There are several reasons for the declining mortality 
rates, but the main factors are early and increased detection rates of PC, in 
combination with advances and changes in treatments (Collin et al. 2008; Etzioni et 
al. 2008).  
In Finland, PC has been the most common cancer diagnosed among males since 
1993 with 4715 new diagnoses (31.4% of all new cancer cases) in 2011 (Fig.2a) 
(Pukkala and Rautalahti 2013). Since the middle of the 1980s PC has been the 
second leading cause of cancer death with 882 deaths attributed to PC (14.4% of all 
cancer deaths) in 2011 (Fig.2b) (Pukkala and Rautalahti 2013). The incidence of PC 
has remained stable in Finland during the most recent years, but mortality has 
decreased by 3.1% per year since 2000 (Center et al. 2012). 
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(a) 
	  	  
(b) 	  
	  
 
Figure 2. Cancer incidence (a) and mortality trends (b) including PC (with prediction) among Finnish males 
(Finnish Cancer registry) (Pukkala and Rautalahti 2013) (Copyright permission 7.1.2014). 
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5.3 Risk factors 
 
At present, three well-established risk factors for developing clinical PC have been 
identified. First, older age is a significant risk factor. In post-mortem studies a 
microscopic foci of PC was found in 15-29% of men aged 30-40 years. By the age of 
70, a histological PC was identified in 60% of men and this rose to 80% who had 
some form of PC by the age of 80 (Sakr et al. 1993; Sakr et al. 1994). Second, 
ethnicity is a well-established risk factor for PC. For example, in the United States 
African Americans have a higher PC incidence rate than the white population. The 
results from Surveillance, Epidemiology, and End Results (SEER) program showed, 
that age-adjusted PC incidence between 2002 and 2006 for the white population was 
153.0/100 000 as compared to 239.8/100 000 for the African American population 
(Horner et al. 2009). Third, heredity is also an established risk factor for PC. Men 
with an affected first-line relative (i.e. father or brother) have at least a doubled risk 
for PC (Steinberg et al. 1990). If two or more first-line relatives have this disease, 
the risk increases approximately 5 to 11 -fold (Bratt 2002; Hemminki 2012; Jansson 
et al. 2012). It has been estimated that in about 9% of men with PC, the disease has a 
true hereditary background with a strong genetic component. The definition of 
‘hereditary PC’ includes the criteria that three or more relatives are affected or at 
least two relatives have early-onset PC before 55 years of age (Hemminki 2012). 
There also exists a wide range of additional and exogenous factors, such as alcohol 
and food consumption, chronic inflammation, pattern of sexual behaviour, ultraviolet 
radiation exposure, that may be potential risk factors for PC, but have not produced 
definitive evidence of the association (Gronberg 2003; Schmid et al. 2007). 
 
5.4 Classification 
 
5.4.1 Histology 
 
Prostatic adenocarcinoma is the most common malignancy in the prostate and it 
comprises over 90% of cases (Bostwick 1989). Although the majority of PCs are 
typical acinar adenocarcinomas, between 5-10% can be considered as variants 
(Grignon 2004; Mazzucchelli et al. 2008), i.e. mucinous adenocarcinoma, ductal 
adenocarcinoma and intraductal carcinoma. There are also several other primary and 
secondary tumours that may involve the prostate, but they are rare. Other primary 
tumour types, from the epithelial origin, are small cell carcinoma, basal cell 
carcinoma, urothelial carcinoma and mucin-producing urothelial type 
adenocarcinoma. Tumour types of mesenchymal origin are prostatic stromal tumours 
of uncertain malignant potential (STUMP) and prostatic stromal sarcoma (Osunkoya 
2012). Other variants of prostatic adenocarcinoma include pseudohyperplastic 
adenocarcinoma, adenosquamous carcinoma, atrophic adenocarcinoma, foamy gland 
adenocarcinoma, adenocarcinoma with carcinoid-like morphology, adenocarcinoma 
with Paneth-like neuroendocrine differentiation, adenocarcinoma with sarcomatoid 
differentiation, signet ring cell adenocarcinoma and adenocarcinoma with 
neuroendocrine differentiation. Neuroendocrine differentiation in PC tumour has 
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been reported to follow androgen deprivation therapy and it has been hypothesized 
to be involved in the progression to castrate-resistant and metastatic PC (Alberti 
2010). The treatment of unusual variants of PCs may be challenging as some of 
these subtypes can behave aggressively and do not respond to conventional 
therapies, such as hormonal therapy (Osunkoya 2012).  
The most common secondary malignancy that involves the prostate through 
direct extension is that of the urinary bladder. In radical cystoprostatectomy series 
the incidence of prostatic involvement with urothelial carcinoma of the bladder is 
reported to be 12-48% (Schellhammer et al. 1977; Revelo et al. 2004).  From other 
sites, the metastases to the prostate typically arise from the lung, gastrointestinal 
tract, kidney, skin, testicle or endocine organs. The incidence of secondary tumours 
in the prostate is 0.1-6.0% (Johnson et al. 1974; Zein et al. 1985; Bates et al. 2002). 
High-grade prostatic intraepithelial neoplasia (HGPIN) is presumed to be a 
premalignant lesion for PC. This is based on its common presence adjacent to PCs. 
HGPIN is defined as architecturally benign prostatic ducts and acini lined by 
atypical or dysplastic epithelial cells. In the prostate biopsy the expected incidence 
of HGPIN is 5-8% and the median risk for PC following HGPIN on needle biopsy is 
estimated to be 24% (Epstein et al. 2006). 
 
5.4.2 Grading, Gleason score 
 
The current standard for histological grading of prostatic adenocarcinoma is based 
on the Gleason score system (Gleason 1966). It replaced the previously widely used 
World Health Organisation (WHO) differentiation grading system that is still 
generally used for grading other malignant tumors. The Gleason grading system is 
based on the pattern of tumour growth, not just single nuclei or cells. The Gleason 
grade ranges from 1 (the least aggressive) to 5 (the most aggressive). The Gleason 
score that consists of two summed grade patterns, ranges from 2-10. The Gleason 
grading system was updated by the International Society of Urologic Pathology 
(ISUP) consensus conference held in 2005. According to the current standard for 
Gleason grading, the most extensive and the highest grade should be incorporated 
into Gleason score in prostate biopsy, not the two most common patterns as in the 
earlier version (Epstein et al. 2005). In radical prostatectomy (RP) specimens the 
most and the second most common Gleason grade should be reported in addition to 
the presence and proportion of the tertiary grade (Epstein et al. 2005). Two well-
known problems related to the Gleason grading are the tendency for upgrading from 
prostate biopsy to the RP specimen and interobserver variability (Iczkowski and 
Lucia 2011). 
The Gleason score is currently the most important prognostic factor for PC 
(Epstein 2010). A variety of different nomograms and prediction models have been 
created to be able to predict more accurately the status and prognosis of disease. In 
case of PC, Kattan nomograms and Partin tables can be considered the most 
commonly known nomograms and with PSA value, clinical stage and Gleason score 
of the tumour, it is possible to predict the presence of an indolent cancer (Kattan et 
al. 2003) or draw up the risk classification of the progression of PC (Partin et al. 
2001).  
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5.4.3 Staging, TNM classification 
 
The extent of PC is commonly classified by the TNM -staging system. Table 1 
presents the 2009 TNM classification (Sobin et al. 2009). Clinical TNM (cTNM) 
stage is estimated at the time of diagnosis and pathological TNM (pTNM) stage can 
be issued only after surgical treatment as tissue samples are required for pTNM 
staging. The definition of clinical T stage is currently based on DRE and transrectal 
ultrasound (TRUS). Positron emission tomography/computed tomography 
(PET/CT), MRI and novel TRUS techniques are not routine practice in PC staging 
(Turkbey et al. 2009). Accurate staging is essential for prognosis assessment. In 
addition, treatment selection differs for localized (T1-T2N0M0), locally advanced 
(T3-4, NX-N0, MX-M0) and metastasized (T1-4, N1 or M1) PCs. 
 
Table 1. TNM classification of PC (version 2009) (Sobin et al. 2009). 
T - Primary tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor not palpable or visible by imaging 
T1a Tumor incidental histologic finding in 5% or less of resected tissue 
T1b Tumor incidental histologic finding in more than 5% of resected tissue 
T1c Tumor identified by needle biopsy 
 
T2 Tumor confined within the prostate 
T2a Tumor involves one-half of one lobe or less 
T2b Tumor involves more than one-half of one lobe but not both lobes 
T2c Tumor involves both lobes 
 
T3 Tumor extends through the prostatic capsule 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invading seminal vesicle(s) 
 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles  
(e.g., external sphincter, levator muscles, rectum, and/or pelvic wall) 
 
N – Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
M – Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
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5.5 Diagnosis 	  
The most commonly used modalities in the diagnostics of PC are a measurement of 
serum PSA, DRE, and TRUS -guided biopsies (Heidenreich et al. 2013). 
5.5.1 Prostate-specific antigen and other markers 
 
PSA was characterized in 1970s (Ablin et al. 1970; Wang et al. 1979) and after mid- 
1980s it became available for clinical use as an important tumour marker and 
potential screening tool for the detection of PC (Stamey et al. 1987; Catalona et al. 
1991). PSA is a kallikrein-like serine protease that liquefies semen and is secreted by 
the epithelial cells of the prostate. A higher level of PSA indicates a higher risk for 
PC (Schröder et al. 2008). PSA is an organ-specific and not a cancer-specific tumour 
marker, also other conditions such as benign prostatic hyperplasia (BPH), prostatitis, 
ejaculation, urinary retention, prostate biopsy, and transurethral resection of prostate 
(TURP) may elevate the levels of serum PSA at least temporarily (Dalton 1989; 
Brawn et al. 1991; Neal et al. 1992; Yuan et al. 1992; Oesterling et al. 1993b; Nadler 
et al. 1995; Herschman et al. 1997; McNeill and Hargreave 2000). 
Although PSA concentration is a continuous variable, a cut-off point of 4 
ng/ml was originally considered to be the upper limit for a normal PSA value 
(specificity 59% and sensitivity 79%) (Catalona et al. 1991). Currently, a PSA value 
of 3 or 3.1 microg/l should be considered for World Health Organization (WHO)-
calibrated assays in order to have the same sensitivity/specificity (Stephan et al. 
2009). The positive predictive value of PSA values for PC > 4.0 ng/ml has been 
estimated to be 32% (Catalona et al. 1994). The results from the Prostate Cancer 
Prevention Trial (PCPT), suggest a cut-off point of 4.0 ng/ml, whereby up to 15% of 
PCs may be left undetected. Notably, 15% of these PCs were graded as Gleason 7 or 
higher  (Thompson et al. 2004). Age-adjusted reference values have been proposed 
instead of a single PSA cut-off value. These age-adjusted values take into account 
the increase in PSA due to BPH with advancing age (Oesterling et al. 1993a). 
 The percentage of free PSA (%fPSA) in serum is calculated as the free to 
total PSA ratio, which has been shown to improve the specificity of PSA testing in 
PC detection conditions and low free PSA percentage is associated with a higher risk 
of PC (Catalona et al. 1995; Luderer et al. 1995; Chen et al. 1996; Elgamal et al. 
1996; Partin et al. 1996; Van Cangh et al. 1996; Catalona et al. 1998). Generally, the 
free to total PSA ratio has been considered an especially useful marker in patients 
with a total PSA concentration range between 2.1-10 ng/ml (Kobori et al. 2008). A 
number of derivatives of serum PSA value, such as PSA density (PSAD) (Benson et 
al. 1992), PSA doubling time (PSADT) (Schmid et al. 1993) and PSA velocity 
(PSAV) (Carter et al. 1992) have been considered to improve the diagnostic 
accuracy of PSA testing and to enhance early detection of PC. Previous prospective 
studies indicate that the use of these in everyday clinical practice has not been 
demonstrated to be superior compared to the use of serum total PSA value alone 
(O'Brien et al. 2009; Vickers et al. 2009; Heidenreich et al. 2013).    
 Messenger RNA (mRNA) of the PC antigen 3 (PCA3) gene is found to be 
overexpressed in >95% of primary PC cells (Bussemakers et al. 1999). PCA3 is 
therefore used as a biomarker and is measured in urine sediment after prostatic 
massage. It has been suggested to be marker independent of the serum PSA level, 
	   21	  
prior prostate biopsy or prostate volume (Deras et al. 2008). PCA3 has shown 
potential as an adjunct marker in PC diagnostics, but due to its lack of sensitivity it 
cannot replace the PSA test in clinical practice and its value as a first-line diagnostic 
test is indefinitely limited (Roobol 2011). The PCA3 score may be combined with 
the serum PSA value and other clinical risk factors into a nomogram, that may be 
used in decision-making concerning biopsy/rebiopsy (Auprich et al. 2011).   
 
5.5.2 Digital rectal examination 
 
Before the PSA era, DRE was practically the main method for detection of PC 
(Gerber et al. 1993; Kavasmaa et al. 2013). Approximately every fifth PC (18%) is 
detected by a suspicious DRE finding alone, regardless of the PSA value (Carvalhal 
et al. 1999). DRE is not very specific, since only 40-50% of cases with abnormal 
DRE findings have PC on biopsy (Philip et al. 2005). The risk of PC is higher in 
cases of an abnormal DRE finding, and especially when combined with an increased 
serum PSA value (Carvalhal et al. 1999; Gosselaar et al. 2008a). An abnormal DRE 
finding is also associated with high-grade PCs (Okotie et al. 2007). 
 
5.5.3 Transrectal ultrasound and prostate biopsies 
 
TRUS is the most common imaging method to examine the prostate. Abnormal areas 
in TRUS have been associated with PC (Dahnert et al. 1986; Lee et al. 1986; 
Gosselaar et al. 2008b). The classic finding of PC on gray-scale ultrasound is 
described as a hypoechoic lesion, but cancer foci may also be visualized as being 
isoechoic or even hyperechoic (Muldoon and Resnick 1989; Flanigan et al. 1994; 
Tzai et al. 1995). It has been estimated that over 40% of PC lesions are isoechoic and 
approximately 5% appear as hyperechoic (Ellis and Brawer 1994). Sensitivity and 
specificity for conventional gray-scale TRUS are 39-75% and 40-82%, respectively 
(Heijmink et al. 2011). Standard TRUS technique has a limited role in detecting or 
staging early PC (Onur et al. 2004), because of particularly low accuracy (52-62%) 
(Heijmink et al. 2011). Many PCs are not visible on standard TRUS and the positive 
predictive value of hypoechoid lesions is only in the 25-30% range (Rifkin et al. 
1990). Colour Doppler scanning combined with TRUS can improve the detection of 
PC (Rifkin et al. 1993). Some new ultrasound techniques have also been developed 
to improve the detection of PC. These innovative techniques, such as ultrasound with 
contrast agents, 3-D and 4-D sonography and elastography have shown promising 
results compared with standard TRUS in PC diagnosis (Balaji et al. 2002; Halpern et 
al. 2005; Miyanaga et al. 2006; Yi et al. 2006; Abul et al. 2007).    
 TRUS-guided prostate biopsy is the standard method for histopathological 
diagnosis of PC (Hara et al. 2008; Takenaka et al. 2008). The basic sextant biopsy 
protocol was introduced in the late 1980s to enhance the accuracy of PC diagnosis 
(Hodge et al. 1989). The PC detection rates can be improved by increasing the 
number of targeted regions and biopsy cores (Eskew et al. 1997; Babaian et al. 2000; 
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Ravery et al. 2000; Emiliozzi et al. 2004; Eskicorapci et al. 2004). Moreover, the 
extended biopsy scheme with 12 biopsy cores has replaced the sextant biopsy 
protocol. Despite increasing the number of cores, the risk of adverse events (i.e. 
bleeding, infection, voiding dysfunction, pain) is not increased (Eichler et al. 2006). 
A 12-core systematic prostate biopsy scheme, that includes apical and far-lateral 
core sampling in a template distribution, has been shown to be a compromise 
between maximal detection of PCs, whilst avoiding rebiopsies and it provides 
sufficient information about the disease (Bjurlin et al. 2013). Taking more than 12 
biopsy cores does not seem to increase the benefit substantially (Eichler et al. 2006), 
but in selected cases it may be reasonable to increase the number of biopsy cores. 
Typically, saturation biopsies (i.e. template with ≥20 and transition zone included) 
are considered, when prostate biopsies are repeatedly negative, but when there is still 
a high suspicion of PC (Scattoni et al. 2010). In selected cases saturation biopsy can 
be performed with transperineal approach to improve the detection of PC (Moran et 
al. 2006).  
 
5.5.4 Imaging 
 
CT and MRI have generally been considered to have a limited role in detecting and 
staging PC. Despite high specificity (>80%), CT has low sensitivity (<30%) in the 
local staging of PC (Tarcan et al. 1996; Yu and Hricak 2000) and a minor role in 
terms of detection and staging PC (Platt et al. 1987; Hricak et al. 2007). The MRI 
allows a functional assessment with modalities such as diffusion-weighted MRI 
(DWI-MRI), magnetic resonance spectroscopy imaging (MRSI), dynamic contrast-
enhanced MRI (DCE-MRI) and these MRI techniques can be used for the detection 
and staging of PC (Ravizzini et al. 2009). The sensitivity and specificity of PC 
detection and local staging with MRI vary considerably with the population and the 
technique used (Turkbey et al. 2009).  Indefinitely, PET scanning does not play a 
significant role in the detection or localization of PC due to its invasive nature, high 
costs and availability of other imaging modalities such as MRI (Heijmink et al. 
2011). However, if TRUS-guided biopsies and MRI are negative, PET scanning can 
be used and it may provide additional advantages especially when combined with 
other imaging modalities, such as MRI (Heijmink et al. 2011). CT and MRI are 
currently the main imaging modalities commonly used for staging nodal PC, 
although they have similar, equally low sensitivity for evaluation of lymph node 
metastases (Hovels et al. 2008). Radionuclide bone scan (scintigraphy) after a 
technetium-99m injection is the current standard method for investigating potential 
bone metastasis in high-risk PC patients. The guidelines of The European 
Association of Urology (EAU) have recommended bone scanning in those cases of 
poorly differentiated PC (Gleason score >7) and locally advanced disease (≥cT3), 
irrespective of the serum PSA level. For patients with a PSA value <20 ng/ml bone 
scanning is recommended in the presence of symptoms or poorly differentiated 
tumour (Heidenreich et al. 2008).  Despite the high sensitivity of scintigraphy, it 
suffers from a lack of specificity, and therefore other imaging modalities, such as 
18F-choline PET/CT are under active evaluation (Even-Sapir et al. 2004; Jadvar 
2013). 
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5.6 Prostate cancer screening 
 
The objective of PC screening is to reduce overall and PC-specific mortality and to 
improve men´s QOL by preventing locally advanced and metastatic disease (Baum 
2013). Elevated PSA is the most important diagnostic tool of PC in early detection 
programmes although other diagnostic measures, such as DRE have been used.  
Currently, there is no general consensus about recommended population-based 
screening for all men to detect early PCs (Ilic et al. 2011).  
Two major randomized controlled studies are ongoing that evaluate 
population-based PC screening. The European Randomized Study of Screening for 
Prostate Cancer (ERSPC) (Schröder et al. 2003; Schröder et al. 2009) and the 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (Andriole et 
al. 2009) have the capacity to evaluate better the efficacy of PC screening. Both 
ERSPC and PLCO trials were initiated in the early 1990´s. ERSPC is a multicenter 
trial conducted in eight European countries. In practice, ERSPC consists of several 
smaller screening trials each of which has its own criteria for the age of participants, 
screening intervals, threshold for a positive screening result and type of recruitment. 
In general, the ERSPC trial included a total of 162 243 men aged 55-69 years and 
they were randomized to the PSA screening group (offered PSA measurement about 
once every 4 years) or to unscreened control group (Schröder et al. 2009). The 
PLCO was initiated in the USA and has more congruent criteria. The PLCO 
randomized 76 693 men to receive annual screening with PSA and DRE or standard 
care as the control (Andriole et al. 2009). The main end-point of these two major 
studies is PC-specific mortality, but in addition, QOL and cost-effectiveness are also 
analyzed. 
Both ERSPC and PLCO reported their interim data in 2009. The ERSPC trial 
showed a significant reduction of 20% in PC mortality in the screening group after a 
median follow-up of nine years (Schröder et al. 2009). After adjustment for 
contamination (i.e. control group participants who sought opportunistic PSA 
screening) and noncompliance (i.e. men in the screening group who did not 
participate in the screening), the mortality reduction was shown to be up to 31% 
(Roobol et al. 2009). The cumulative incidence of PC was 8.2% in the screening 
group and 4.8% in the control group. The results showed the absolute risk difference 
to be 0.71 death per 1000 men, that is 1410 men would have to be screened and 48 
additional PC cases would have to be treated to prevent one death from PC 
(Schröder et al. 2009). Moreover, the updated analysis after a median follow-up of 
11 years showed a decrease in both of these numbers; based on recent results, 1055 
would have to be screened and 37 treated to prevent one PC death. The relative risk 
reduction for PC-specific death was shown to be 21% in favour of PC screening 
(Schröder et al. 2012). 
The Swedish part of the ERSPC, the Göteborg screening trial, published the 
mortality results separately (Hugosson et al. 2010). This trial was initiated in 1994 as 
an independent study, but joined the ERSPC soon after. With a follow-up of 14 
years, the study detected a mortality reduction of 44% in the screening arm, 
accompanied by a significant risk of over-diagnosis. The differences compared to the 
ERSPC and also the probable reasons for different results are longer follow-up, 
younger age at screening, shorter screening interval (2 years) and lower PSA 
threshold (3.0 ng/ml).  
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The PLCO trial did not find a PC mortality benefit in the screening arm. This result 
has been explained by contamination of the control arm. The contamination was 
extensive in the control arm since over a third of participants had undergone PSA 
testing and DRE within the first year of the study and half of the participants had 
PSA testing during the trial (Andriole et al. 2009).  
The results of the ERSPC and the PLCO trials, as evaluated by the major 
urological societies indicated that widespread population-based mass screening for 
PC is not recommended at present. The EAU recommends early detection of PC (i.e. 
opportunistic screening) in well-informed men instead of mass screening. A baseline 
PSA level should be determined at the age of 40 and screening intervals should be 
adapted to this baseline PSA serum concentration thereafter. An interval of 8 years 
might be appropriate for screening in men with baseline levels of ≤ 1 ng/ml. PSA 
testing is not recommended in men > 75 years as early detection of PC would not 
have any impact clinically (Heidenreich et al. 2013). The American Urological 
Association (AUA) do not recommend PSA screening for the following categories: 
men < 40 years, men 40-54 years of age at average risk, men > 70 years of age or 
life expectancy less than 10-15 years. They recommend shared decision making for 
men 55-69 years of age and a screening interval of ≥ 2 years (Carter et al. 2013). 
 
5.6.1 QOL aspects related to the PSA screening process 
 
PC screening has been shown to reduce PC-related mortality and the rate of 
advanced disease. Reduction in mortality from PC is the primary endpoint in the 
screening trials, but QOL is also a major aspect, and often expressed as quality-of-
life adjusted gain in life years (QALYs). The problem of overdiagnosis related to 
screening has already been emphasized (Djulbegovic et al. 2010; Ilic et al. 2011). 
However, more confirmed data from randomized trials is needed as reports about the 
benefits and harmful effects of PSA screening have varied widely and are rather 
inconsistent (Ilic et al. 2007; Crawford and Abrahamsson 2008). Recently, data from 
the ERSPC trial concluded that the benefit of PSA screening was diminished by the 
loss of QALYs owing to post diagnosis long-term effects. Before more general 
recommendations regarding PSA screening can be made, data from longer-term 
follow-up, data on long-term effects of PC treatments, and AS data on QOL are also 
needed (Heijnsdijk et al. 2012). 
 Previous studies have shown that PSA screening participants do not 
experience any significant increases in anxiety levels, even with an abnormal PSA 
result (Essink-Bot et al. 1998; Brindle et al. 2006). The screening process does not 
seem to affect substantially the health status of individuals in the short-term; the 
exception to this is the short-lasting side effects of having a prostate biopsy (Essink-
Bot et al. 1998). In addition, only men who have a tendency to anxiety have 
experienced higher levels of anxiety and distress during the screening process 
(Essink-Bot et al. 1998). In general, men seem to cope well through the PSA 
screening process, although a minority of participants experience distress at the time 
of prostate biopsy, which is not entirely resolved even by a negative screening result 
(Macefield et al. 2010). Screening for disease does not appear to have long-term 
negative emotional impact on participants (Collins et al. 2011) and the screening 
process itself has only little if any effect on participant´s psychological health 
(Awsare et al. 2008; Macefield et al. 2010). 
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5.7 Treatment options with curative intent 
 
At present there are various treatment options available for PC, depending on the 
clinical stage of the disease. The options for localized PC with curative intent are 
AS, radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy 
(BT) and focal therapy. AS is hereafter discussed in the review as a separate entity. 
Currently the lack of randomized controlled trials makes the comparison of 
treatment modalities difficult.  
 
5.7.1 Radical prostatectomy 
 
RP is a surgical procedure to remove the prostate gland. Open retropubic RP has 
been the most commonly used technique, but recently robot-assisted radical 
prostatectomy (RARP) has become a commonly used option for open surgery 
(Novara et al. 2012b). Patients with a life expectancy of over 10 years and local 
disease are generally considered suitable, and the goal for RP is the eradication of 
PC while saving urinary continence and potency if possible (Bianco et al. 2005). 
Data from the Cancer of the Prostate Strategic Urological Research Endeavor 
(CaPSURE) database has showed that RP is at present the most common treatment 
in men with localized PC and approximately half of these patients undergo RP 
procedure in the US (Cooperberg et al. 2010). A carefully selected patient population 
with high-risk and more advanced PC (PSA>20 ng/ml with clinical stage T3 and/or 
Gleason score 8-10 in biopsy) may also benefit from RP (Spahn et al. 2010; Gontero 
et al. 2011).  
Two prospective randomized trials reported a PC-specific survival benefit 
from RP compared with watchful waiting (WW). The Scandinavian Prostate Cancer 
Group Study Number 4 (SPCG-4) reported that compared to WW a reduction in the 
rate of death from PC, and at 15 years the absolute risk reduction was 6.1% 
following randomization to RP (Holmberg et al. 2012). The subanalysis of this study 
clarified, that individual prediction of benefit of RP varies widely depending on age 
and PC characteristics. The absolute 10-year PC mortality reduction in the RP group 
was 4.5% for low-risk versus 17.2% for high-risk patients, in men at 65 years of age 
(Vickers et al. 2012).  The other randomized trial, the Prostate Cancer Intervention 
Versus Observation Trial (PIVOT) showed a benefit attributable to RP in men < 65 
years of age, but only in those who had only an intermediate or high risk of PC 
progression (Wilt et al. 2012).  
It would be more acceptable to treat all PC patients when radical treatment 
did not cause any side effects or decrease QOL. Nevertheless, each treatment 
modality for localized PC has side effects, even in the long-term after treatment 
(Sanda et al. 2008; Litwin et al. 1995; Mols et al. 2009). The improvement in 
surgical techniques including the introduction of RARP, have resulted in advantages 
in postoperative recovery and functional outcomes (Novara et al. 2012b; Novara et 
al. 2012a; Ficarra et al. 2012a; Ficarra et al. 2012b). However, urinary incontinence 
and erectile dysfunction remain significant parts of the side effect profile of RP. The 
rates of urinary incontinence and erectile dysfunction after surgery vary widely 
between published reports. Approximately 8% of men that have undergone RP, have 
persisting urinary incontinence a year after the operation (Murphy et al. 1994). 
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Nerve-sparing techniques can be considered in a patient with organ-confined disease 
and reported potency rates after bilateral nervesparing RP varied between 31 and 
86% (Dubbelman et al. 2006).  
 
5.7.2 External beam radiation therapy 
 
EBRT is one of the primary treatment modalities for patients with localized or 
locally advanced PC. It is also commonly used in cases that suggest a greater 
likelihood of non-organ-confined disease. Radiotherapy continues to be an important 
and valid alternative to surgery as a radical treatment for PC. In EBRT, radiation is 
delivered to the prostate gland via an external energy source. Three-dimensional 
conformal radiation therapy (3D-CRT) has been the gold standard for EBRT in 
many countries, and if possible, intensity-modulated external-beam radiotherapy 
(IMRT), with or without image-guided radiotherapy (IGRT), is currently 
recommended (Bauman et al. 2012; Heidenreich et al. 2013). IMRT is an optimized 
form of 3D-CRT and by using implanted fiducial markers in the gland it enhances 
the ability to escalate radiation dosage without additional toxicity. To optimize 
outcomes of EBRT, a dose of ≥74 Gy is recommended for treating low-risk PC 
(Kupelian et al. 2005). For intermediate- and high-risk PC a dose escalation from 76 
to 81 Gy has been shown to have a significant positive impact on 5-year progression-
free survival (Kupelian et al. 2008; Krauss et al. 2011). One possibility for treatment 
of intermediate- or high-risk PC, is the combination of EBRT with low- or high-dose 
brachytherapy. Androgen-deprivation therapy is also recommended to be combined 
with EBRT to improve overall survival in patients with high-risk localized PC 
(D'Amico et al. 2008; Jones et al. 2011). The risk for side effects of EBRT increases 
with dose-escalation and patients are informed about potential later gastrointestinal 
or genitourinary toxicity, and possible adverse effects of EBRT on erectile function. 
The most typical side effects related to radiation therapy include gastrointestinal 
symptoms such as rectal bleeding and proctitis and genitourinary symptoms such as 
urgency, haematuria and incontinence (Budaus et al. 2012; Mohammed et al. 2012; 
Schmid et al. 2012). According to retrospective surveys, the effects of radiotherapy 
on erectile function are reported to be less than those of RP (Fowler et al. 1996). One 
of the long-term effects and risks related to radiotherapy is the development of 
radiation induced secondary malignancy, such as rectal or bladder cancer  (Murray et 
al. 2013) 
 
5.7.3 Brachytherapy 
 
BT refers to the treatment of PC using ionizing radiation that is delivered via 
radioactive seeds placed in the prostate gland. The low-dose rate brachytherapy 
(LDR-BT) approach is transperineal and done under TRUS guidance. In LDR-BT, 
permanent low-energy radioactive implants, i.e. iodine-125 or palladium-103, are 
inserted into the prostate. LDR-BT is indicated in patients with low-risk PC (Ash et 
al. 2000). The updated consensus guidelines for LDR-BT in patient selection, 
optimal technique and follow-up, were recently published (Davis et al. 2012). In 
high-dose rate brachytherapy (HDR-BT) iridium-192 high-radiation source is 
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implanted temporarily into the gland. HDR-BT can be used in combination with 
EBRT for more aggressive and advanced PC tumours. The analyses of a BT series 
demonstrated good results for the oncological outcome (Sylvester et al. 2011; Morris 
et al. 2013). The main side effect profile of BT includes a risk of urinary retention 
(1.5-22%), incontinence (0-19%) and a risk for post-implantation transurethral 
resection of the prostate (required in up to 8.7% of cases) (Budaus et al. 2012). 
Erectile dysfunction develops in about 40% of men 3-5 years after BT (Heidenreich 
et al. 2013).  
 
5.7.4 Focal therapies 
 
The number of smaller PCs detected at an earlier stage, has increased during the past 
two decades due to the screening. Focal treatment, such as cryosurgical ablation of 
the prostate (CSAP) and high-intensity focused ultrasound (HIFU) therapy, has 
emerged as a treatment option in men with clinically localized small focus PC and 
for whome RP is not indicated (Babaian et al. 2008; Crouzet et al. 2010; Warmuth et 
al. 2010). Although recent studies have shown promising results (Donnelly et al. 
2010), the long-term efficacy data are still lacking (Heidenreich et al. 2013). Known 
complications related to CSAP include acute urinary retention, erectile dysfunction 
(45-100%), urethral sloughing (0-6%), incontinence (2-4%), and fistula formation 
(<1%). Potential complications after HIFU are erectile dysfunction (13-53%), 
incontinence (1-15%), urethral stricture (4-14%), urinary retention (1-9%) and 
rectourethral fistulae (0-3%)(Nguyen and Jones 2011).  	  
5.8 Hormonal therapy 
 
Hormonal therapy is mainly used in patients with locally advanced or metastasized 
PC, in postponing clinical progression and reducing symptoms. The principle behind 
endocrine therapy is to eliminate androgens (by chemical or surgical castration) or 
androgen action (antiandrogens) and hence achieve an inhibitory effect on PC cells. 
When prostate cells are deprived of androgenic stimulation they undergo apoptosis. 
The elimination of androgens can be achieved by suppressing the secretion of 
testicular androgens, i.e. surgical castration or with chemical castration by using 
luteinising hormone-releasing hormone (LHRH) agonists, with or without 
antiandrogens. In recent years LHRH antagonists have also become available for 
chemical castration. Immediate androgen deprivation therapy compared with 
deferred therapy initiated at the time symptomatic progression occurs, gives a 
modest improvement in overall survival, but not in disease-specific survival, except 
in patients with aggressive PC (Studer et al. 2013). Data of SPCG-7/SFUO-3 trials 
suggest that when androgen deprivation therapy in combination with radiotherapy is 
compared with endocrine treatment alone, it halves the 10-year PC-specific mortality 
and decreases overall mortality in men with locally advanced disease or high-risk 
local PC (Widmark et al. 2009). Hormonal treatment can also be used as a 
neoadjuvant or adjuvant therapy. In cases of locally advanced PC, for which 
	   28	  
immediate androgen suppression with LHRH agonists given during and for three 
years after EBRT, improved disease-free and overall survival (Bolla et al. 2002).   
There are many side effects related to hormonal therapy. Castration is 
associated with hot flushes, loss of energy, loss of libido, loss of potency, 
osteoporosis, weight gain, nausea, vomiting and mood swings. Patients on long-term 
conventional androgen deprivation therapy may also have a higher risk of 
cardiovascular disease (Bourke et al. 2012). The main side effects associated with 
antiandrogens are gynecomastia and breast pain (Iversen et al. 2010).  
 
5.9 Active surveillance 
5.9.1 Rationale for active surveillance 
 
Over the last two decades, the proportion of low-risk PCs in which earlier detection 
did not change the prognosis, has increased (Welch and Black 2010). This 
phenomenon is described by the term overdiagnosis. The most significant evidence 
for PC overdiagnosis comes from randomized screening trials. PSA-based PC 
screening has led to the overdiagnosis of indolent tumours in up to 50% of cases 
(Draisma et al. 2003). AS has emerged as an alternative strategy for managing these 
potentially overdiagnosed PCs. The objective of this strategy is to avoid, or postpone 
the treatment of PC, and thereby diminish the possible adverse effects of radical 
treatments (Parker 2004). Radical treatment of all men with low-risk PC, would 
cause a considerable amount of unnecessary side effects, such as incontinence and 
impotence (Pardo et al. 2010) that have adverse effects on QOL (Sanda et al. 2008). 
The specific approach of AS is to initially withhold radical treatments (i.e. surgery or 
radiation therapy), but reserve the opportunity to deferred treatment with curative 
intent in the case of disease progression or reclassification observed during follow-
up. During AS, patients are intensively monitored using such tools as repetitive PSA 
measurements, clinical examination including DRE and prostate biopsies. 
The basis for using the AS strategy is the substantial evidence and knowledge 
of the long natural history of PC. Post-mortem studies have shown that the 
prevalence of indolent PCs is high in aging men; in about 50% of men in their fifties 
harbour histological evidence of PC and the rate increases with age (Sakr et al. 
1994). Such tumours are not likely to progress or their growth potential is so slow 
that these patients are likely to die of other causes than PC. Widespread PSA-based 
screening and extended-pattern biopsy schemes have led to an increasing trend in 
overdiagnosis (Draisma et al. 2003; Welch and Black 2010). 
A Gleason score of 6 for PC has been seen as a part of the aging process 
(Sakr et al. 1994). A Gleason score of 6 PC has been shown not to have the 
characteristic hallmarks of many other cancers, which are: apoptosis resistance, 
sustained angiogenesis, local tissue invasion/metastasis, unlimited replicative 
potential, insensitivity to antigrowth signals and self-sufficiency to growth signals 
(Guo et al. 1997; Skacel et al. 2001; Padar et al. 2003; Pasquali et al. 2006; True et 
al. 2006; Susaki and Nakayama 2007; Mucci et al. 2009; Hanahan and Weinberg 
2011; Ross et al. 2011; Bismar et al. 2012; Fleischmann et al. 2012). The 20-year 
outcomes following conservative management, based on the Albertsen WW cohort 
before the PSA testing era, reported a mortality rate of 22% for Gleason score of 5 or 
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6 PC (Albertsen et al. 2005b). However, ERSPC data indicate that screen-detected 
PCs are diagnosed approximately 10 years earlier (Schröder et al. 2010). The 
Gleason grading system was changed in 2005 (Epstein et al. 2005), which resulted in 
the relative upgrading of the disease; it has been estimated that one-third of patients 
(with a Gleason score 6 PC) in the Albertsen study would be upgraded according to 
the current grading system (Albertsen et al. 2005a). Of importance is that, the 
grading of the tumours in the WW series is based on biopsy rather than surgical 
staging, which is known to underestimate the proportion of higher grade PCs. A 
study of 12 000 men with pathologically confirmed Gleason score 6 PC after RP, 
found that 0.2% progressed to the metastatic phase during the 20-year follow-up, but 
after the re-analysis the same individuals of this group upgraded to Gleason 4 pattern 
(Eggener et al. 2011). Similar results were reported for a RP series of 14 000 men 
with a Gleason score 6 cancer of which only 22 had lymph node metastases and 
these PCs upgraded into Gleason score ≥7 after re-analysis (Ross et al. 2012). It 
could be concluded that the prevailing current thinkings suggest Gleason score 6 
cancer to be only a risk factor for clinically significant PC rather than a cancer with 
metastatic potential itself. 	  
5.9.2 Watchful waiting versus active surveillance 
 
AS emerged from the experience of WW. The term ‘watchful waiting’ is used to 
describe the conservative approach to management of PC. The rationale for this 
observational strategy is the finding that PCs often progress slowly and are 
diagnosed in elderly men with high incidence of comorbidity. WW aims to avoid or 
at least delay treatment and the related side effects, and thus helps maintain the 
QOL. When treatment is required, it is palliative only. By contrast, patients on AS 
should be initially fit for radical treatment. The AS strategy aims to diagnose 
clinically significant disease and if it occurs during follow-up, offer deferred radical 
treatment with curative intent only when needed. Hence, avoidance of unnecessary 
morbidity from overtreating PCs is a desired objective. This observational strategy 
was first described in 2002 (Choo et al. 2002).  
 
5.9.3 Definition of clinically insignificant prostate cancer 
 
The aggressiveness of PC is partly defined by its pathological characteristics, i.e. 
pathological stage, differentiation grade and tumour volume. The terms ‘indolent’ 
and ‘clinically insignificant’ have been widely used for low-risk asymptomatic PCs. 
These terms are often used interchangeably. However, the term ‘insignificant’ takes 
the clinical aspect more into account, whereas the term ‘indolent’ refers to the 
pathological features (Ploussard et al. 2011b). Frequently used criteria for indolent 
PC include pathological stage T2, absence of Gleason pattern 4/5 and tumour 
volume less than 0.5ml in a RP specimen (Epstein et al. 1994). The tumour volume 
threshold of <0.5 ml is based on only a modest series of cystoprostatectomies taken 
before PSA testing era ensured (Stamey et al. 1993). Recent ERSPC trial data 
suggest a cancer volume of 1.3 ml as a cut-off point for indolent Gleason score 6 
(stage ≤T2) PC (Wolters et al. 2011). 
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Clinical criteria that combines clinical and biopsy findings were based on 
histological data. Currently, the definition for low-risk PC as described by D’Amico 
is the most widely accepted: i.e. a PSA of less than 10 ng/ml, Gleason score of 6 or 
less, and nonpalpable tumour or palpable in less than half of one lobe of the prostate 
(i.e. T1c or T2a)	   (D'Amico et al. 1995). A more strict definition (Epstein criteria) 
distinguishes the very low-risk PC into separate category, as defined as a PSAD of 
<0.15 ≤50% PC involvement of any biopsy core, and maximum of two positive 
biopsy cores	   (Epstein 2011), the other low-risk PCs fulfill the D’Amico criteria. 
Various nomograms have also been developed to assess the probability of indolent 
or low-risk PC (Bangma et al. 2009). 
 
5.9.4 Patient selection for active surveillance 
 
The most effective AS programme would reliably be able to recognize the patients 
with the more aggressive disease and the need for active treatment early after 
diagnosis. Although there exists no randomized trials that compare selection criteria 
for AS, several prospective AS series have provided a feasible basis for indentifying 
appropriate patients using this management strategy (Dall'Era et al. 2008; van As et 
al. 2008; Klotz et al. 2010b; Soloway et al. 2010; Adamy et al. 2011; Tosoian et al. 
2011; Bul et al. 2013b). Patients who are considered candidates for AS should be fit 
for radical treatment, thus comorbidities and age are essential issues in the AS 
decision-making process. Eventually, treatment decision for patients with localized 
early stage PC should take into account several things such as age, comorbidities, 
personal preferences, estimation of the aggressiveness of the PC and potential 
benefits and risks of radical treatments (Smith 2011). Although the specific inclusion 
criteria for AS vary by institution and there is also a wide range of criteria, the 
majority of criteria are similar and offer a common basis for patient selection. These 
include low clinical stage (T1-T2), low PSA (<10-15 ng/ml), well-differentiated PC 
(Gleason score< 7 in most series) and small volume tumour in the biopsy. The 
inclusion criteria of largest prospective AS trials are listed in Table 2. 
 
Table 2. Inclusion criteria of largest AS studies. 
Institution  PSA Clinical Gleason    PC positive     Single core    Other  
    stage score    biopsy cores   positivity   
PRIAS  
(van den Bergh et al. 2007) ≤ 10 T1-T2 ≤ 3+3    ≤ 2  NR    PSAD < 0.2 
 
University of Toronto  
(Klotz et al. 2010b)  ≤ 10 T1c ≤ 3+3*    NR  NR    - 
 
University of Miami 
(Soloway et al. 2010) ≤ 10 ≤ T2a ≤ 3+3    ≤ 2  ≤ 20%    - 
 
UCSF  
(Dall'Era et al. 2008) ≤ 10 ≤ T2a ≤ 3+3    ≤ 33%  NR    - 
 
Johns Hopkins  
(Tosoian et al. 2011) - T1c ≤ 3+3    ≤ 2  ≤ 50%    PSAD ≤ 0.15 
 
Royal Marsden Hospital  
(van As et al. 2008)  ≤ 15 ≤ T2a ≤ 3+4    ≤ 50%  NR    - 
 
MSKCC  
(Adamy et al. 2011)  ≤ 10 ≤ T2a ≤ 3+3    ≤ 3  ≤ 50%    -   
* Until 2000 for men over 70: GS≤3+4, PSA≤15 
MSKCC = Memorial Sloan Kettering Cancer Center; NR=not recorded; PSAD=PSA-density; UCSF = University of California, San Francisco 
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Most of the AS protocols accept only patients with a Gleason score of 6 PC and the 
presence of Gleason pattern 4 is considered a contraindication for AS. However, 
previous studies have shown promising results, and suggest that a small amount of 
Gleason pattern of 4 might still be categorized as indolent disease and these patients 
should also be considered as candidates for AS, since the progression rates have not 
differed significantly from Gleason score 6 PCs (Choo et al. 2002; Cooperberg et al. 
2011b; Bul et al. 2012b). This approach may be more applicable in older patients 
(over >65 years) or in men with short life expectancy and comorbidities (Klotz 
2013). 	  
5.9.5 Monitoring and triggers for intervention 
 
The aim of intensive monitoring during AS is to identify those patients with 
biologically aggressive PC missed initially or PCs that have developed during 
surveillance, but which are still at a curable stage. Each AS protocol has its own 
follow-up strategy and there is no preferable way of monitoring. Contemporary AS 
protocols monitor potential progression by means of PSA testing, clinical 
examination by DRE and by prostate biopsy. Monitoring includes repetitive 
measurements of serum PSA (e.g. at 3-month intervals) and based on these 
measurements the PSADT or PSAV values can be calculated. A rebiopsy is 
performed at one year of surveillance and in most AS protocols biopsy are repeated 
at least every 3 to 4 years. The common triggers for intervention (Table 3) include 
Gleason progression to ≥7 or higher tumour volume in prostate rebiopsy, short 
PSADT (a cut-off value ranging between ≤2 and ≤4 years), increasing PSA velocity, 
changes on serial imaging or patient’s request mainly due to increased anxiety.  
 
 
Table 3. Triggers for intervention in AS series.  
Institution  Triggers for intervention 
PRIAS  
(van den Bergh et al. 2007) PSADT<3 years; GS≥7; >2 positive cores 
 
University of Toronto  
(Klotz et al. 2010b)  PSADT≤3 years; T stage progression; GS upgrade 
 
University of Miami 
(Soloway et al. 2010) GS ≥7; increase of positive cores, increase of core involvement 
  
UCSF  
(Dall'Era et al. 2008) GS≥7; PSAV>0.75ng/ml per year  
 
Johns Hopkins  
(Tosoian et al. 2011) GS≥7; >2 positive cores; >50% core involvement  
 
Royal Marsden Hospital  
(van As et al. 2008)  Primary GS≥4; PSAV>1ng/ml per year; >50% core involvement 
 
MSKCC  
(Adamy et al. 2011)  PSA≥10; GS≥7; >3 positive cores; >50% core involvement  
GS=Gleason score; PSADT=PSA doubling time; PSAV=PSA velocity 
MSKCC = Memorial Sloan Kettering Cancer Center; UCSF = University of California, San Francisco 
 
 
Changes of serum PSA value over time seem to be a trigger for treatment less often 
than upgrading the classifications or Gleason scores in rebiopsies (Dall'Era et al. 
2008). PSADT is a trigger for active treatment in about 10-20% of cases (Bul et al. 
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2012c) and a short PSADT (i.e. ≤3 years) has been shown to be associated with 
adverse rebiopsy findings (Bul et al. 2012a). However, some recent studies have 
questioned the association between PSA kinetics and reclassification or adverse 
rebiopsy results in the short-term (Ross et al. 2010; Whitson et al. 2011), and 
therefore PSA kinetics are often combined with information from DRE and biopsy. 
In addition to being an invasive procedure with potential morbidity, prostate biopsy 
often underestimates the grade and stage of the disease (Stav et al. 2007). This 
creates the need for the development of novel biomarkers and imaging technology, 
such as MRI, to improve AS. 
 
5.9.6 Outcomes of active surveillance studies 	  
5.9.6.1 Treatment free-survival, PC-specific mortality and overall 
mortality  
 
Despite the varying inclusion criteria of AS studies, PC-specific and overall 
mortality rates are low in the short-term (Table 4). The longest median follow-up 
(6.8 years) of AS was reported for the Toronto cohort, in which the 5- and 10-year 
PC-specific survival rates were 99.7% and 97.2%, respectively (Klotz et al. 2010b). 
This patient cohort includes men with low-risk and intermediate-risk (30%) PCs. 
Men > 70 years had PSA values of up to 15 ng/ml and Gleason scores ≤ (3+4). The 
median age of patients in this AS series was relatively high (70.3 years), which 
probably explains the high all-cause mortality rate (overall survival 78.6%). AS 
study by Johns Hopkins University reported results with no PC deaths or metastatic 
cases, after a median follow-up of 2.7 years (Tosoian et al. 2011). In this study the 
patients fulfilled strict criteria for very low-risk PC, i.e. the Epstein criteria. A 
retrospective study from the ERSPC, on 988 participants and a median follow-up of 
3.91 years, reported 10-year PC-specific survival of 100%	   (van den Bergh et al. 
2009b). The prospective PRIAS AS study reported a treatment-free survival of 
77.3% after 2 years, a median follow-up of 1.6 years and PC-specific survival of 
100% (Bul et al. 2013b). 
 
5.9.6.2 Outcomes from deferred treatment 
 
As PC progress or is reclassified beyond the initial inclusion criteria, deferred radical 
treatment is often recommended. The results from PRIAS data showed, that patients 
who discontinued AS due to protocol deviations, 14% had a Gleason score of ≥4+3 
and 19% extracapsular extension (Bul et al. 2012c). This is in concordance with 
previous studies. Several previous studies have examined RP series that compared 
deferred to immediate treatments and no significant differences were observed in 
pathological outcome or in biochemical recurrence rates (Warlick et al. 2006; van 
den Bergh et al. 2010b; Holmstrom et al. 2010; Dall'Era et al. 2011). Furthermore, a 
nationwide cohort study in the United States showed similar rates for PC mortality in 
men with low-risk PC who chose deferred treatment on AS and those who were 
treated immediately (Shappley et al. 2009). The majority of AS patients, about 2/3 
remain treatment free, and metastatic cases and PC mortality are shown to be rare in 
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prospective AS trials (van As et al. 2008; Dall'Era et al. 2008; Klotz et al. 2010a 
Tosoian et al. 2011). However, the longest AS cohort study from Toronto reported a 
biochemical recurrence rate of 50% in radically treated men, which represented 13% 
of the total patient cohort (Klotz et al. 2010b). 
 
 
Table 4. Summary of survival results of AS series. 
Institution  Size of Median  Median ATFS OS CSS 
   cohort follow-up   age (%) (%) (%) 
    (months) (years) 
PRIAS    2494 19 65 76 97.1 100 
(Bul et al. 2013b)   
 
University of Toronto  453 82 70 70 78.6 97.2 
(Klotz et al. 2010b)   
 
University of Miami  230 32 64 86 100 100 
(Soloway et al. 2010)  
 
UCSF    321 47 64 54 97 100 
(Dall'Era et al. 2008)  
 
Johns Hopkins   769 32 66 54 98 100 
(Tosoian et al. 2011)  
 
Royal Marsden Hospital  326 22 67 73 98 100 
(van As et al. 2008)   
 
MSKCC    238 22 64 - - -  
(Adamy et al. 2011)  
ATFS = active treatment-free survival; OS = overall survival; CSS = cancer-specific survival 
MSKCC = Memorial Sloan Kettering Cancer Center; UCSF = University of California, San Francisco 
  	  
5.9.6.3 Rebiopsy outcomes  
 
Most of the AS trials include prostate rebiopsy as a part of surveillance strategy. 
This is based on the assumption that the Gleason grade is a significant predictor for 
PC prognosis. The data from radical prostatectomy specimen showed that 
preoperative clinical undergrading is common, it is estimated to be 20-30% with a 
standard 12-biopsy core system (Conti et al. 2009; Smaldone et al. 2010; Suardi et 
al. 2010). In most cases, Gleason classification upgrading is likely to be due to the 
more accurate resampling than true disease progression (Porten et al. 2011).  The 
results from the PRIAS study indicated the risk of reclassification towards higher 
risk of PC in 21.5% of men in 1-year rebiopsies (Bul et al. 2012a). Higher PSAD 
and number of positive biopsy cores at diagnosis (2 versus 1) were predictive of a 
higher grade and a higher volume PC at rebiopsy. Several other studies have 
reported reclassification rates between 13-55% (Venkitaraman et al. 2007; Ng et al. 
2009; Ross et al. 2010; Tseng et al. 2010; Adamy et al. 2011; Isharwal et al. 2011; 
San Francisco et al. 2011; Whitson et al. 2011). In many of these studies PSAD has 
also shown to be a significant baseline predictor for reclassification in rebiopsy 
(Venkitaraman et al. 2007; Ng et al. 2009; San Francisco et al. 2011). 
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5.9.7 Psychological and QOL aspects  
 
The principal aim of AS is to avoid or delay side effects of radical treatment, but one 
concern is the possible psychological burden on the patient caused by the knowledge 
of having an untreated cancer.  Men with low-risk PC may experience anxiety during 
AS and this may have negative effects on their QOL (Bacon et al. 2001; Galbraith et 
al. 2001; Litwin et al. 2002). Men on a surveillance-like strategy may be unsettled 
due to a perception of danger and this may negatively influence their QOL (Wallace 
2003). However, recent studies showed that patients with low-risk PC and on AS, do 
not seem to have higher anxiety or distress levels in the short-term. During a nine- 
month period, anxiety and distress levels remained relatively low, but those patients 
with a more neurotic personality and lower physical health scores reported higher 
anxiety and distress levels (van den Bergh et al. 2009a; van den Bergh et al. 2010a). 
Previous studies also suggest that AS is not significantly associated with 
psychological distress when compared to immediately treated patients who received 
radiotherapy with or without hormonal therapy (Burnet et al. 2007). Patients on AS 
have been shown to have comparable generic- and disease-specific health-related 
quality of life (HRQL) dimensions compared to patients treated with EBRT. Patients 
on AS had fewer problems with bowel function than patients who had received 
radiation therapy. Patients treated by radiation therapy also reported significantly 
more problems with erectile function. HRQL of patients on surveillance was 
comparable to age- and sex- matched normative population up to 10 years after 
diagnosis (Thong et al. 2010). Surveillance, unlike immediate treatment, was 
associated with QOL benefits as a long-term decrease in the risk of urinary 
incontinence and impotence. QOL outcomes were not worse in patients who had 
delayed treatment after initial surveillance compared to those who had immediate 
treatment (Kasperzyk et al. 2011). AS has also been reported to have the highest 
quality-adjusted life expectancy, when compared with radiation therapy, 
brachytherapy or radical prostatectomy (Hayes et al. 2010). Serial prostate rebiopsies 
may have an adverse effect on erectile function, but no significant effect on lower 
urinary tract symptoms has been observed (Fujita et al. 2009). 
The majority of the patients seem to be satisfied with the choice of 
surveillance and only a limited number of men were reported to be afraid of PC 
progression (Latini et al. 2007). Communication, education and peer-support groups 
can be beneficial to ease anxiety concerning AS (Pickles et al. 2007). 
Discontinuation of AS and a change to deferred radical therapy are not often due to 
anxiety or distress (Cooperberg et al. 2011a). The patients who have chosen 
expectant management (WW) as their treatment option, have similar or even better 
HRQL scores compared to men without PC at the beginning of the surveillance, but 
many of HRQL domains are affected by increasing age and scores decrease over 
time (Arredondo et al. 2008). Longer follow-up is needed to be able to assess the 
long-term psychological and QOL effects of AS. Ongoing studies, such as the 
Prostate testing for cancer and Treatment (ProtecT) study that randomize treatments 
of patients with low-risk PC, may offer more information about QOL effects of AS 
(Lane et al. 2010). 	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5.9.8 Imaging  
 
The role of imaging in AS patients is currently under extensive investigation. MRI 
seems to be the most promising imaging modality. Since the early 1980s, MRI has 
been used to evaluate the anatomy of the prostate and PC disease (Steyn and Smith 
1982). The utility of MRI is its accurate representation of soft tissue anatomy, high 
spatial resolution, and the possibility for functional measurements to be taken, e.g. 
spectroscopy. These advantages have led to the active evaluation of the role of MRI 
in the diagnosis and staging of PC (Lindner et al. 2010).  T2-weighted MRI was 
initially used for tumour localization, but benign conditions (i.e. prostatitis, 
haemorrhage) were found to have a similar appearance. T2-weighted MRI has a 
varying sensitivity (46-96%) and a low specificity (54-82%) in tumour localisation 
(Wefer et al. 2000; Engelbrecht et al. 2002; Kirkham et al. 2006). Hence, other MRI 
modalities were developed namely: diffusion weighted MRI (DW-MRI), which 
measures the diffusion of water molecules in tissue; dynamic contrast-enhanced MRI 
(DCE-MRI), which utilizes the microvascular properties of tissue and MR 
spectroscopy (MRSI), which measures metabolite levels (creatine, choline, citrane, 
polyamides) in tissue. The multiparametric approach i.e. combinations of these 
modalities (T2 weighted imaging combined DW-MRI and/or DCE-MRI and/or 
MRSI) accurately rules out clinically important lesions, and has negatively 
predictive values for high grade PCs (Villers et al. 2006; Delongchamps et al. 2011; 
Somford et al. 2013). A large cancer lesion under MRI in a patient with PC has a 
high predictive value for clinically significant disease (Futterer et al. 2009; Villeirs 
et al. 2011). A study reported that multiparametric MRI also has a significant 
correlation with Gleason score, but significant overlap between different grades still 
existed (Hambrock et al. 2011).  
Multiparametric MRI has been used to target biopsies at suspicious lesions. 
Previous results report PC detection rates of 41% with (median 4 cores) MRI guided 
targeted biopsy in men with previous negative TRUS-guided 12-core random 
biopsies (Hoeks et al. 2012). The majority of cancers detected (87%) were clinically 
significant. Multiparametric MRI in combination with MRI guided biopsy may thus 
have a role in risk classification at diagnosis and during follow-up in AS patients. 
The role of MRI in AS has not yet been fully determined, although it has been 
shown to aid in the detection of the anteriorly located tumours (Lawrentschuk et al. 
2010). Guidelines have been developed for prostate MRI including imaging 
acquisition protocols and a structurized reporting system to improve the reproducible 
and reliability of MR images with standardised methods and technologies (Barentsz 
et al. 2012; Moore et al. 2013). Accurate interpretation of MRI is challenging and 
requires experience that can result in significant interobserver variability 
(Mussurakis et al. 1996). MR imaging is not assumed to replace the histological 
verification of PC, but to help decrease the frequency of rebiopsy and biopsy-related 
morbidity in patients on AS (Turkbey et al. 2011b; Turkbey et al. 2012). 
 
5.9.9 Biomarkers 
 
Potential serum and urine biomarkers for PC have been intensively studied in basic 
research laboratories for the past decade. Future novel biomarkers may make it 
possible to improve the risk rating of PC at an early stage. Unfortunately, no 
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clinically relevant markers have been validated as relevant prognostic factors in AS 
as yet. Isoforms of PSA, such as combination of free PSA and -2ProPSA (Isharwal 
et al. 2011) are under evaluation. Prostate cancer antigen 3 (PCA3) was initially 
promising, as it was shown to be associated with PC volume (Ploussard et al. 
2011a). However, results about its accuracy in predicting stage and grade of PC were 
contradictory (Roobol 2011). The PCA3 marker has also been studied in an AS 
cohort, but no association was found with biopsy progression after a short follow-up 
(Tosoian et al. 2010). Further evaluation is needed to clarify the role of PCA3 in AS. 
 
5.9.10 The role of 5-Alpha Reductase Inhibitors 
 
Two randomized, placebo-controlled trials, The Prostate Cancer Prevention Trial 
(PCPT) (Thompson et al. 2003) and The Reduction by Dutasteride of Prostate 
Cancer Events trial (REDUCE) (Andriole et al. 2010) found an approximately 25% 
reduction in overall PC incidence in men taking 5-alpha reductase inhibitors (5-
ARI). These results suggest that men on AS may benefit from using 5-ARI, but these 
two studies also reported a 0.5% increase in high-risk PC in 5-ARI users. A 
retrospective study on 5-ARI use in men on AS found, that men with low-risk PC, 
who were using 5-ARI had a favourable prognosis compared to those without 5-ARI 
medication (Finelli et al. 2011). A prospective study, The Reduction by Dutasteride 
of Clinical Progression Events in Expectant Management trial (REDEEM), 
randomized men on AS between dutasteride and placebo. The results showed a 
reduced risk of PC progression in 5-ARI users and no increase in high-grade PC 
after 3 years (Fleshner et al. 2012). This study suggests that men on AS may benefit 
from the use of 5-ARI in reducing the risk of reclassification on rebiopsy. 
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6. AIMS OF THE STUDY 
 
Active surveillance is an alternative option for immediate radical treatments in 
patients with low-risk PC. The aim of this initial expectant management strategy is 
to avoid or postpone the risk of side effects from radical treatment. The overall 
objective of the present study was to evaluate the feasibility of AS as a management 
option for low-risk PC and further analyse the QOL issues during the continuum of 
the PC disease. 
 
 
The specific aims of the study were: 
 
 
I. to evaluate the short-term outcomes of the prospective international PRIAS 
study (study I). 
 
II. to analyse the effects of AS on the HRQL and urinary and erectile function 
(study II). 
 
III. to observe the short-term effects of various phases of PC screening on HRQL 
(study III). 
 
IV. to assess the role of DW-MRI interpreted in a routine clinical setting, as a 
diagnostic and prognostic tool in AS (study IV).  
 
V. to evaluate the utility of a free/total PSA ratio as a prognostic tool in AS 
(study V). 
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7. MATERIALS AND METHODS 
 
PRIAS is an international prospective trial that originates from the ERSPC. In this 
dissertation the data from the PRIAS study is used in two articles (I, V), and the data 
from the Finnish arm of the PRIAS study is used in two articles (II, IV). The data 
from the Finnish arm of ERSPC is used in one article (III). 
 
7.1 Study populations 
 
7.1.1 The Finnish arm of the ERSPC trial (study III) 
 
ERSPC is a multicenter, population-based and randomized PC screening trial that 
commenced in the early 1990´s and is conducted in eight European countries. In the 
first screening round (1996-1999) in Finland, 80 144 men were identified from the 
population registry and randomized into screening (31 866) or into the control arm 
(48 278). The men were born between 1929-1944 and were living in the Helsinki or 
Tampere metropolitan areas. Men who had emigrated, or deceased prior to the 
screening invitation, and with previous PC diagnosis (identified from the Finnish 
Cancer Registry) were excluded. A PSA blood sample was drawn from 20 793 
participants (30 190 invited, response 69%). 
7.1.2 The PRIAS study (studies I, II, IV and V) 
 
In 2006 the PRIAS study was initiated in the Erasmus University Medical Center in 
the Netherlands and between December 2006 and July 2008 the first 500 
international patients were included in the PRIAS trial (I). The PRIAS study is still 
ongoing and the number of participating countries and centres has also increased 
(Figure 3). In Finland, the PRIAS commenced in Helsinki University Central 
Hospital and since 2007, the PRIAS study expanded under the name of the national 
FinnProstate Study XI (FPXI) into eight other clinics in Finland. Between December 
2006 and May 2009, the first 124 patients had been included in the study; 80 of these 
participants had been followed for at least a year by May 2009 (II). Between 
February 2009 and May 2011, 80 of Finnish PRIAS patients underwent DW-MRI in 
Helsinki University Central Hospital (IV). Men were included between December 
2006 and October 2013 from the international PRIAS data, a free PSA value was 
determined in 939 patients at the study enrolment (V). The RP data used in the 
analysis was available from the Finnish arm of the PRIAS study (V). 
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Figure 3. Distribution of PRIAS patients (n= 3744) inclusions (largest medical centers included, i.e. > 8 study 
participants) per country (at 29 October, 2013). 
 
7.2 Study protocols and study design 
 
7.2.1 Study III the Finnish arm of the ERSPC trial  
 
Men were invited for a blood test to determine their serum PSA concentration in the 
screening arm. Men with PSA 3.0-3.9 ng/ml were referred to DRE, and since 1998 a 
determination of the free/total PSA ratio was used as an ancillary test in these 
screening participants. Men with a PSA value over 4 ng/ml were referred to a full 
clinical examination, whereas DRE was used as an ancillary standalone test for men 
with marginally elevated PSA values. Men with a PSA ≥ 4 ng/ml or a suspicious 
finding in DRE or free/total PSA ratio < 0.16 were referred for diagnostic 
examination i.e. TRUS with prostate biopsy. In the screening arm, men received a 
re-invitation to the second and third screening rounds that were arranged four and 
eight years after the first round. The men were invited for the latter rounds, 
regardless of previous participation or non-response to screening. 
 
7.2.2 Studies I, II, IV and V protocol 
 
The protocols for studies I, II, IV and V are based on the PRIAS study. The PRIAS 
inclusion criteria are histologically confirmed adenocarcinoma of the prostate with a 
PSA level ≤ 10 ng/ml, clinical T –class (cT) ≤ 2, a Gleason score ≤ 6, a maximum of 
two positive biopsies and PSA density < 0.2 ng/ml. A patient should be fit for 
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curative treatment and have no history of previous PC treatments to be considered a 
candidate for the PRIAS study. The patients in studies I, II, IV and V were 
intensively monitored during AS. PSA was measured every 3 months and DRE 
every 6 months during the first two years after diagnosis. Thereafter, PSA was 
measured every 6 months and DRE was performed annually. Prostate rebiopsies 
were standard and were taken 1, 4 and 7 years after enrolment in the study. If 
PSADT was between 3 to 10 years, annual rebiopsies were advised. The criteria for 
discontinuation of surveillance and deferred active treatment were PSADT less than 
3 years, cancer in more than two rebiopsy cores or Gleason score higher than 6. If 
PSA exceeded over 20 ng/ml, a bonescan was recommended (Fig.4). 
 
 
Figure 4. Studies I, II, IV and V based on the PRIAS protocol. 
 
 
A prostate volume-dependent number of random biopsies was also advised, but not 
obligatory. The recommendation for the number of biopsies was: prostate volume < 
40 ml 8 biopsies, 40-60 ml 10 biopsies, > 60 ml 12 biopsies (Vashi et al. 1998). In 
Finland, 12 TRUS-guided random biopsies were routinely taken. The measurement 
of free PSA was not mandatory according to the study protocol, but many of the 
participating centres had incorporated free PSA measurement into the study visit 
plan (V). 
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In the analysis of the first 500 PRIAS patients (I), the main outcome parameter was 
active treatment-free survival. Secondary endpoints included reasons for 
discontinuation of AS, findings in the standard 1-year rebiopsies, and outcomes after 
RP. Distributions of PSADT, DRE findings and preliminary survival were also 
analysed. 
 
7.2.3 PRIAS internet website 
 
The PRIAS trial has its own website that can be found at www.prias-project.org. The 
site offers general information about AS of PC and the PRIAS study itself and is 
available to the public. The web-based tool within the website is used for the 
inclusion and follow-up of study participants. After logging in using a personal 
account, physicians have access and can include new patients and search for follow-
up details of their own study participants. PSADT is calculated automatically and the 
site also generates a graph presenting the patient´s PSA values over time. The 
PRIAS website provides automatic individualized recommendations, such as 
whether continuation of AS is indicated according to the protocol or not. The 
Erasmus University Medical Center in Rotterdam is the co-ordinating study centre 
that maintains the PRIAS website. 
 
7.2.4 RAND 36 – Item Health Survey (II, III) 
 
The Finnish version of RAND 36-Item Health Survey (Hays et al. 1993) was used in 
two studies (II, III) to analyse HRQL. The RAND-36 questionnaire is validated and 
had good reproducibility in the Finnish population (i.e. Cronbach´s α 0.80-0.94). 
Age-stratified reference values were also available, which made the comparison with 
the general population possible (Aalto et al. 1999). The RAND-36 questionnaire 
included 36 items that were further divided into eight subscales: physical 
functioning, bodily pain, general health perceptions, mental health, role limitations 
due to physical and emotional problems, social function and vitality. Each of the 
eight subscales was scored from 0 to 100 and a higher score indicated better HRQL.  
The PRIAS protocol does not require the use of any particular standard 
quality of life-survey. In Helsinki University Hospital, the RAND-36 questionnaire 
was chosen to evaluate effects of AS on participants’ general QOL and to allow 
comparisons across different treatments and diseases. QOL is monitored at the study 
inclusion and in surveillance at 3, 5, and 7 years. One year QOL questionnaire was 
answered by the patients before the first rebiopsy. At the same time, points relating 
to voiding symptoms and erectile function were also evaluated using the well-
validated and standardized IPSS and IIEF-5 questionnaires (II). 
The quantification of the impact of the screening process on HRQL was 
achieved when RAND-36 questionnaires were delivered to the screening participants 
at each of the five phases of the first screening round: 500 at invitation, 500 after a 
PSA test, 500 after the PSA result, 314 after DRE (before information of its result, 
but aware of the PSA value); and >300 after TRUS and biopsy (before information 
of its result, but aware of the PSA value)(Fig.5). Additional copies of questionnaires 
were made and delivered without keeping track of the exact numbers in one 
department. Consequently, the exact number of delivered questionnaires after TRUS 
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and biopsy is not available. Participants were different in each of the five phases and 
were asked to fill in RAND-36 questionnaires. Information on sociodemographic 
and behavioural factors was also collected at invitation, attendance and partly at PSA 
result phases, but was not ancillary to either the screening test by DRE or the 
diagnostic examination (TRUS/biopsy) phases. The questionnaires were delivered 
with the invitation letter, which also included information about the study and PC in 
general (III). 	  
   
Figure 5. Flow chart of the recruitment of study (III) participants 
 
7.2.5 MRI (IV) 
 
MRI is not a mandatory part of the PRIAS protocol, but in Helsinki University 
Central Horpital, DW-MRI was incorporated into the follow-up protocol and 
patients had the opportunity to have DW-MRI after a year of AS, before the first 
rebiopsy (IV). MRI was performed with 3T T2-W MRI (Philips Medical Systems) 
with using a body-array coil. Echo-planar DW-MRI images (with b-values 0 s/mm2, 
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300 s/mm2, 600 s/mm2) were obtained transverse to the prostate parallel to the 
corresponding set of T2-W images. The analysis of T2-W MRI images was 
quantitative and for the analyses the prostate was divided into seven regions (right 
apex, middle, basis, left apex, middle, basis and anterior part). Low T2 signals in the 
peripheral zone and in the central area were considered suspicious for malignant 
lesion. T1 images were also analysed to rule out benign processes (e.g. prostate 
hyperplasia or haemmorrhage) and to ensure that high signal areas did not exist in 
the same locations. DW-MRI images and apparent diffusion coefficient (ADC) maps 
were compared with each other and the appearance of the lesion in bright contrast in 
DW-MRI and low signal intensity on ADC, was considered suspicious for 
malignancy. MRI images were interpreted by two genitourinary radiologists and 
results were made available, as a written report, to the clinicians at the patient´s first 
rebiopsy follow-up visit. 
 
7.2.6 Statistics 
 
The Statistical Package for the Social Sciences (SPSS) was used for data analyses. 
The cut-off level of statistical significance was set at p=0.05 in all tests. Values are 
expressed as median and range, unless stated otherwise.  
The differences in means of the RAND-36 questionnaire scores were 
analysed using the paired/non-paired t-test, or when non-parametric by the Mann-
Whitney U-test, depending on the groups and distribution of the data. A ‘half SD 
rule’ was used to interpret the QOL data, i.e. a change in QOL variables more than 
0.5 SD was considered clinically significant (Norman et al. 2003). Correlation 
analysis and Pearson chi-squared test clarified the associations between patients´ 
characteristics and HRQL variables. Binary and ordinal logistic regression analyses 
further interpreted the associations between HRQL variables and assumed HRQL 
predicting factors (II, III). Spearman´s rank coefficient correlation analysis and 
Pearson chi-squared test were used to assess the associations between clinical 
variables/rebiopsy findings and DW-MRI results. Logistic regression was used to 
analyse assumed predictors of deferred radical treatment (IV) and to explore 
potential predictors of adverse rebiopsy findings (I, V). Active treatment-free 
survival was assessed using the logrank test and graphically displayed by the 
Kaplan-Meier survivorship method (I, V). Time to treatment change and association 
of patients’ baseline characteristics and adverse RP findings were analysed using the 
Cox regression (V). Hazard ratios were estimated together with the associated 95% 
confidence interval and p-values (V).  
 
7.2.7 Ethics 
 
The Ethics Committees of Helsinki University Central Hospital and Tampere 
University Hospital approved The Finnish Prostate Cancer Screening Trial protocol. 
The PRIAS study protocol was approved by The Ethics Committee of Helsinki 
University Central Hospital in 2006. In other PRIAS centers (I, V), the study 
protocol was approved by the respective ethics committees in each participating 
country.	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8. RESULTS 
 
8.1 The short-term outcomes of the first 500 PRIAS 
patients (study I) 
 
Table 5 shows the baseline characteristics of the first 500 patients in the PRIAS 
study (I). At the time of analysis the median follow-up was 1.02 years. The 2-year 
active treatment-free survival (ATFS) rate was 73%. Figure 6 presents the total 
ATFS and also stratifies the reasons for discontinuing AS. A considerable drop in 
the survival curve was observed for all reasons, at biopsy and also at PSADT at 1 
year of follow-up.  
 
 
Table 5. The characteristics of study patients (study I). 
Variable    At diagnosis 
    Median (25-75 percentiles) 
Age, year    66.0 (60.7-70.4) 
PSA, ng/ml   5.3 (3.9-6.7) 
PSAD, ng/ml/cc   0.12 (0.09-0.16) 
Prostate volume, cm3  42.6 (35.0-56.0) 
DRE      
 T1c   79.2% 
 T2a   19.2% 
 T2b   1.2% 
 T2c   0.4% 
Positive biopsy cores 
 1 core   68.6% 
 2 cores   31.4% 
Gleason score 
 =6   95.0% 
 <6   5.0% 
PSA = prostate-specific antigen; PSAD = prostate-specific antigen density; DRE = digital rectal examination 
 
 
 
 
 
Figure 6. ATFS for discontinuing in AS (total and stratified for reason). 
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At the time of analysis 82/500 (16%) men had already discontinued AS; 83% 
(68/82) due to protocol-based reasons and 17% (14/82) because of anxiety and/or by 
request. The reasons for the discontinuations in protocol were adverse rebiopsy 
findings (Gleason score >6 and/or >2 PC positive rebiopsy cores) for 43% (29/68), 
PSADT for 37% (25/68) and for both reasons combined 19% (13/68). Table 6 lists 
the specific reasons for discontinuation of AS and the active treatments chosen.  
 
 
 
Table 6. Reasons for discontinuation of AS (n=82) and deferred active treatments (study I). 	   	   	    Deferred active treatment 
 
Reason for active treatment  RP RT BT Unknown/other Total 
 
 
Protocol-based 
 
PSADT (only)   7 4 12 2  25 
 
Number of positive cores at  5 5 1 1  12 
rebiopsy and Gleason score 
 
Number of positive cores at  6 1 5 -  12 
rebiopsy 
 
Gleason score at rebiopsy  2 - 3 -  5 
 
PSADT, number of positive   1 - - -  1 
cores at rebiopsy and  
rebiopsy Gleason score 
 
PSADT, number of positive  4 2 - 1  7 
cores at rebiopsy 
 
PSADT and rebiopsy   1 2 1 1  5 
Gleason score 
 
T stage (only)    - - - 1  1* 
Psychological 
 
Anxiety    4 3 - 1  8 
 
 
Other 
 
Request to discontinue on AS - 2 1 1  4 
 
Unknown   1 - 1 -  2 
 
Total    31 19 24 8  82 
*MRI was performed, revealing clinical stage T3a 
BT=  brachytherapy; PSADT = prostate-specific antigen doubling time 
RP= radical prostatectomy; RT= external beam radiation therapy;  
 
 
In total, 261/500 (52%) of study patients had standard rebiopsy and biopsies were 
taken a median of 1.02 (25-75 percentiles: 1.0-1.1) years after PC diagnosis. In the 
rebiopsy the median number of biopsy cores was 10 (25-75 percentiles: 8-12). No 
cancer was found in 34% (90/261), favourable result (i.e. Gleason score ≤6, ≤2 
positive biopsy cores) in 44% (114/261) and unfavourable result (i.e. Gleason score 
>6 and/or >2 positive biopsy cores) in 22% (57/261). Rebiopsy results in relation to 
PSADT at the time of biopsy are shown in Table 7. PSADT was not available in 
14/261 (5%) patients. When PSADT was compared in patients with favourable and 
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unfavourable biopsy results, the difference between the groups was not statistically 
significant (p=0.411). The univariate analysis revealed that only variable predicting 
unfavorable rebiopsy findings was the number of PC positive biopsy cores at 
diagnostic biopsy (two versus one). 17% (32/183) of men with one PC positive 
biopsy at diagnosis also had unfavourable rebiopsy findings and 32% (25/78) of men 
with two positive biopsy cores (p=0.014). Age, prostate volume, PSA, PSADT, 
clinical stage, time to rebiopsy and number of diagnostic/rebiopsy cores had no 
significant association with unfavourable rebiopsy findings. 
 
 
 
Table 7. Rebiopsy findings after 1 year of AS in relation to PSADT at the time of biopsy (n=261) (study I). 
Rebiopsy  Favourable (n=194)  Unfavourable (n=53)  Total 
Findings  No     1-2 positive    Total  >2  ≤2  >2  Total  
PC     cores and    positive positive biopsy 
          Gleason 6   cores, cores, cores, 
    Gleason Gleason Gleason 
    ≤6 >6 >6 
PSADT 
 
0-3 years  24/  30/ 54/  7/ 5/ 3/ 15/ 69/ 
  (28%) (28%) (28%)  (24%) (50%) (21%) (28%) (28%) 
 
3-10 years 18/ 30/ 48/   12/ 1/ 5/ 18/ 66/  
  (21%) (28%) (25%)  (41%) (10%) (36%) (34%) (27%) 
 
>10 years 7/ 8/ 15/  1/ 2/ 0/ 3/ 18/ 
  (8%) (7%) (8%)  (3%) (20%) (0%) (6%) (7%) 
 
Negative  37/ 40/ 77/  9/ 2/ 6/ 17/ 94/ 
  (43%) (37%) (40%)  (31%) (20%) (43%) (33%) (39%) 
 
Unknown  4 6 10  3 0 1 4 14 
 
Total  90/ 114/ 204/  32/ 10/ 15/ 57/ 261/ 
  (34%) (44%) (78%)  (12%) (4%) (6%) (22%) (100%) 
PSADT = prostate-specific antigen doubling time 
 
 
Of the 27 men who underwent RP, 24 (89%) results were available. Patients 
underwent RP a median of 1.0 (25-75 percentile: 0.5-1.1) year after PC diagnosis 
and the study enrolment. The reasons for surgical treatment were: PSADT <3 years 
only (6/27), adverse rebiopsy findings only (10/27), combination of these two 
protocol-based reasons for discontinuation (6/27) and other reasons (5/27). In all 
four cases of T3 tumors, in rebiopsy more than two PC positive cores were found 
and in three of these Gleason scores were also upgraded >6. In 50% (12/24) of RP 
specimens Gleason scores were upgraded; in the rebiopsies of 11 men taken 
previously, unfavorable biopsy characteristics were found in all of them. No 
significant association could be observed between adverse RP findings (Gleason >6 
or T3) and PRIAS inclusion variables or PSADT.  
 The present data do not allow for a mortality analysis. During follow-up, no 
one died of PC. Two patients died due to other reasons and in one patient PC lymph 
node metastases were detected. 
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8.2 Short-term HRQL effects of AS (study II)  
 
In study II, of the enrolled 124 Finnish PRIAS patients (in the area of Helsinki 
University Central Hospital), 105/124 (85%) had completed and returned the 
baseline RAND-36 questionnaire and 19/124 (15%) had not responded by the time 
of analysis. 80 patients had been followed for at least a year and 75 of these (94%) 
had completed the questionnaires at the study inclusion and after one year of follow-
up. The response rates for IPSS and IIEF-5 questionnaires were 80% (60/75) and 
56% (42/75), respectively. The patient characteristics of the study group (75 men 
with baseline and follow-up questionnaires available) and the non-respondent group 
(19) are shown in Table 8. The only significant difference between the groups was in 
the educational backround; the respondents had a significantly higher level of 
education (p=0.02). 
 
Table 8. Characteristics of study patients and non-respondents (study II). 
Variable Study group (N=75) 
N(%)/ median(range) 
(Unless noted otherwise) 
Non-respondents (N=19) 
N(%)/ median(range) 
(Unless noted otherwise) 
p value 
Age at diagnosis, years  
(median, 25th-75th percentiles) 
64 (60-69) 64 (60-69) 0.9 
Initial PSA, ng/ml 5.1(2.0-10.0) 5.0 (1.4-9.3) 0.7 
Initial free PSA, ng/ml 0.7 (0.0-2.8) 0.7 (0.2-1.8) 0.9 
Clinical stage T1 at diagnosis 75 (100) 19 (100)  
One positive biopsy at diagnosis 53 (71) 12 (63) 0.5 
Two positive biopsies at diagnosis  22 (29) 7 (37) 0.5 
Higher education (college/university) 23 (50) 1 (10) 0.02 
Married/living with a partner 51 (67) 13 (68) 0.7 
 
 
After one year of AS, no significant differences in mental (mental health, physical 
role, social function, vitality) or in physical health dimensions (bodily pain, general 
health, physical function, physical role) were observed (Table 9). Slightly inferior 
results were noted in two domains of eight HRQL subgroups, but the differences 
were not statistically significant: bodily pain (p=0.149) and physical function 
(p=0.608) decreased during AS. After follow-up the scores of three HRQL domains, 
i.e. social function, emotional and physical role, were slightly better than at the study 
enrolment. The only statistically significant improvement was observed for physical 
role (p=0.010), but the change was not clinically significant (<0.5 SD). The 
correlation and regression analyses revealed that the assumed HRQL predicting 
factors (i.e. age, diagnostic PSA, PSA change during follow-up at any time point) 
did not correlate or associate with any of the eight HRQL domains at the study 
enrolment or during AS. Compared to the reference values obtained from the general 
Finnish male population (aged 55-64 and 65-74), mean HRQL scores among men on 
AS were significantly better in all eight subgroups of RAND-36 (p<0.05) at 
diagnosis and after follow-up (Figures 7 & 8).  
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During AS follow-up, total IPSS score increased slightly (mean 7.9 vs 9.2, p 
=0.121). In total IIEF-5 score, significant change was not observed (mean 18.8 vs 
19.5, p=0.583). 
 
Table 9. Mean (SD) HRQL in AS patients, measured by RAND-36 questionnaire (study II). 
RAND-36 questionnaire score Baseline, 
at the study inclusion 
mean (SD) 
After a year of AS 
mean (SD) 
p value 
General health 65 (15.2) 65 (16.3) 0.780 
Physical function 91 (13.6) 90 (12.9) 0.608 
Mental health 81 (14.9) 81 (14.1) 0.696 
Social function 91 (14.4) 93 (14.0) 0.279 
Vitality 76 (15.7) 76 (16.0) 0.582 
Body pain 90 (15.6) 87 (18.7) 0.149 
Role physical 81 (34.2) 89 (25.7) 0.010* 
Role emotional 82 (32.6) 88 (29.0) 0.052 
* p <0.05 statistically significant cut-off 
 
 
Figure 7. RAND-36 scores in men aged 55-64 (study II). 
(PF, physical function; PR, physical role; ER, emotional role; VT, vitality; MH, mental health; SF, social function; BP, 
body pain; GH, general health) 	  	  
Figure 8. RAND-36 scores in men aged 65-74 (study II).  
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8.3 Short-term HRQL effects of PC screening (study III) 
 
During the first screening round, the RAND-36 questionnaire was delivered to a 
total of more than 2000 participants in five discrete phases. At the invitation phase 
293/500 men (59%, 4 excluded due to incompletely filled questionnaires) responded, 
at screening 386/500 men (77%, 9 exclusions), at PSA result 271/500 men (54%, 12 
exclusions) and at DRE 217/314 men (69%, 6 exclusions). The exact number of 
questionnaires delivered after the diagnostic examination phase (i.e. TRUS and 
biopsy) is not known, because additional copies of the questionnaires were made and 
delivered without keeping track of the actual numbers at one participating 
department. In total 319 responders were evaluated for this screening phase. In the 
RAND-36 questionnaires, the item ‘non-response rate’ was 0.5-1.5% at each of 
different screening phases. A range of 8.8-12.5% of screening participants did not 
respond to one or more questions. 
The range of mean ages of the participants for the different phases was 60-63 
years (Table 10). Information on sociodemographic and behavioral factors was 
collected at phases 1 to 3 (i.e. invitation, PSA blood test and partly at PSA result 
group), but not at the DRE and TRUS/biopsy phases. No significant differences were 
noted between the screening participants in the sociodemographic and behavioral 
factors at different screening phases (Table 11). 
 
 
 
Table 10. Mean ages of questionnaire respondents at different phases of the PC screening process (study III). 
Screening phase Mean age, years (SD) 
1) Invitation 60.2 (4.6) 
2) PSA blood test 60.7 (4.4) 
3) PSA result 60.8 (4.5) 
4) Digital rectal examination 62.3 (4.3) 
5) TRUS and biopsy 62.8 (4.3) 
 
 
The highest HRQL response scores of the RAND-36 questionnaire (medians of 90-
100) were related to the emotional role, physical role, physical function and social 
function. The lowest scores of RAND-36 were consistently found for general health 
(median 65) at each screening phase and followed by energy/fatigue. No major or 
systematic changes in HRQL could be detected during the screening process (Table 
12). However, a decrease was observed in the emotional role subscale (p=0.005) at 
the ancillary screening test (DRE) phase and a minor but statistically significant 
decrease was found in social function after receiving the PSA result (p=0.035). After 
diagnostic examination (TRUS/biopsy) the pain HRQL score was higher than after 
DRE (p=0.003).  
HRQL scores were higher in patients with abnormal PSA values (PSA ≥3) 
than those with normal PSA values (PSA <3), which was unexpected. No significant 
differences were found between these groups when general health and mental 
dimensions were compared.  
The ordinal regression analysis showed results that were largely 
unremarkable. Significant associations (p<0.01) between age and poorer physical 
function were detected. In contrast, physical exercise with better physical function, 
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energy and general health, improved energy and mental health, and also education 
with physical function and physical role were reported. At DRE phase an unexpected 
association between a higher serum PSA level and better general health scores was 
observed among other findings of borderline significance. 
 
 
Table 11. Socio-demographic and lifestyle factors among study participants (study III). 
 Invitation 
N (%) 
PSA blood test 
N (%) 
PSA result 
N (%) 
Pearson  
Chi-Square  
(p value) 
Employment 
    Full/Part time employed 
    Unemployed 
    Retired 
    Not known 
 
131 (45) 
 25 (9) 
104 (36) 
33 (11) 
 
141 (37) 
52 (13) 
141 (37) 
52 (13) 
 
105 (39) 
26 (10) 
107 (39) 
33 (12) 
 
p=0.173 
 
Position 
    White collar 
    Blue collar 
    Retired 
    Not known 
 
 
84 (29) 
73 (25) 
116 (40) 
20 (6) 
 
 
90 (23) 
104 (27) 
178 (46) 
14 (4) 
 
 
75 (28) 
62 (23) 
121 (45) 
13 (5) 
 
 
p=0.508 
 
Smoking 
    No 
    Yes 
    Not known 
 
 
183 (63) 
107 (37) 
1  
 
 
242 (63) 
142 (37) 
2 
 
 
175 (65) 
96 (35) 
 
 
 
p=0.556 
 
Marital status 
    Unmarried 
    Married/Cohabitation 
    Divorced 
    Widow 
 
 
15 (5) 
240 (82) 
30 (10) 
8 (3) 
 
 
25 (7) 
317 (82) 
29 (8) 
15 (4) 
 
 
*NA 
 
 
p=0.457 
 
Education level 
    Elementary/Secondary school 
    Secondary school graduate 
    Vocational school/institute 
    College  
    University 
    Not known 
 
 
118 (41) 
3 (1) 
75 (26) 
7 (2) 
56 (19) 
34 (11) 
 
 
152 (39) 
7 (2) 
107 (28) 
12 (3) 
66 (17) 
42 (11) 
 
 
*NA 
 
 
p=0.681 
 
Exercise  ≥ ½ hours (leisure time) 
    Not at all 
    Occasionally 
Regularly once a week/ less   frequently 
    Regularly twice a week 
    At least 3 times a week 
    Not known 
 
 
7 (2) 
72 (25) 
40 (14) 
48 (16) 
121 (42) 
3 (1) 
 
 
10 (3) 
80 (21) 
35 (9) 
71 (18) 
183 (47) 
7 (2) 
 
 
*NA 
 
 
p=0.298 
*NA = Not available 
 
 
The comparison of HRQL scores to the reference values (for the subscales) of 
general Finnish age-stratified male population (aged 60-64), showed no significant 
differences; HRQL was similar or slightly better among screening participants 
(Figure 9). 
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Table 12. HRQL as RAND-36 scores (median, 25th–75th percentiles) at five screening phases (study  III). 
*     p = 0.035; 3 vs. 2; **   p = 0.005; 4 vs. 3; ***  p = 0.003; 5 vs. 4 
 
 
 
 
Figure 9.  RAND-36 results at testing compared with age-stratified (60-64) of the general Finnish male 
population (study III). 
 
8.4 DW-MRI after a year of AS and before rebiopsy 
(study IV) 
 
80 PRIAS patients in Helsinki University Central Hospital underwent DW-MRI 
after one year of follow-up but before the first rebiopsy. The characteristics of the 
study patients are shown in Table 13.  
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Social function 100 (75-100) 100(75-100)  95 (75-100) * 100 (75-100) 100(75-100) 
Energy/Fatigue 70 (55-85) 75 (60-85) 75 (60-85) 75 (60-85) 75 (60-85) 
Pain 90 (68-100) 90 (68-100) 90 (68-100) 80 (68-100) 90 (78-100) *** 
Physical role 100 (75-100) 100(75-100) 100 (75-100) 100 (75-100) 100(75-100) 
Emotional role 100 (67-100) 100(67-100) 100 (67-100) 94 (67-100) ** 100(67-100) 
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Table 13. Characteristics of study patients (study IV). 
Variable Study patients (n=80)  
Age at diagnosis (years), median (range) 64 (50-77) 
PSA at diagnosis (ng/ml), median (range) 5.7 (1.4-10.0) 
Free PSA at diagnosis (ng/ml), median (range) 0.9 (0.0-2.8) 
Prostate volume (cc), median (range) 44.2 (16-100) 
Clinical stage T1 at diagnosis (%) 80 (100) 
One positive biopsy core at diagnosis (%) 
 
Two positive biopsy cores at diagnosis (%) 
56 (70) 
 
24 (30) 
 
Gleason score 3+3=6 (%) 
 
78 (97.5) 
 
PC length at diagnostic biopsy, mm (mean % of total biopsy length) 
 
2.1 (1.2) 
 
Rebiopsy 
                  No cancer (%)  
                  Gleason score 6 (%)  
                  Gleason score 7 (%)       
                  Gleason score 9 (%) 
                  No repeat biopsy 
 
 
30 (38.5)  
37 (47.4) 
10 (12.8)  
1 (1.3)  
2* 
 
PC length at rebiopsy, mm (mean % of total biopsy length) 
 
5.0 (2.6) 
* One patient could not undergo rebiopsy due receiving an antithrombotic medication  
and one patient refused rebiopsy 
PC = prostate cancer; PSA = prostate-specific antigen 
 
 
40/80 patients (50%) had a lesion suspicious for malignancy in T2-weighted MRI 
and 30 (75%) of these 40 patients also had a suspicious lesion on their ADC maps, 
generated from DW-MRI sequences. Neither the malignant suspicious lesion in MRI 
(i.e. MRI positivity) nor the tumour ADC revealed any significant correlations with 
clinical variables, such as age, PSA at diagnosis, free PSA, prostate volume, 
percentage of PC at diagnostic biopsy, PSA at discontinuation of AS or PSADT 
(Table 14). No significant associations were detected between MRI 
positivity/tumour appearance in ADC maps and diagnostic biopsy (number of PC 
positive cores, Gleason score), rebiopsy findings (number of PC positive cores, 
Gleason score) or discontinuation of AS (Table 15). Similarly, no significant 
associations were found in a separate analysis of the patient group (n=23) with 
adverse findings in rebiopsy (Gleason score >6 and/or number of PC positive cores 
>2) or discontinuation of AS. 
 
Table 14. Spearman´s correlations between clinical variables and tumour appearance on MRI / ADC maps (study 
IV). 
Study 
population 
(N=80) 
Age Prostate volume 
PSA at 
dg 
                      
% of PC at 
diagnostic 
biopsy 
PSA-DT PSA at discontinuation 
MRI 
r 
p value 
 
0.103 
0.361 
 
0.106 
0.351 
 
0.106 
0.349 
 
-0.222 
0.069 
 
-0.056 
0.411 
 
0.080 
0.560 
ADC 
r 
p value 
 
0.072 
0.525 
 
0.034 
0.768 
 
-0.018 
0.875 
 
-0.219 
0.073 
 
-0.037 
0.745 
 
0.015 
0.898 
r =correlation coefficient; ADC = apparent diffusion coefficient 
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Table 15. Chi-squared analysis between clinical variables and MRI / ADC maps (study IV). 
r =correlation coefficient; ADC = apparent diffusion coefficient; AS = active surveillance 
 
 
Rebiopsy results were available for 78 (98%) of the study patients, including 
information on cancer length and location in biopsy cores. 30/78 (38.5%) patients 
had no cancer on the first rebiopsy. The only significant association for tumour 
location emerged between right middle lobe in MRI and right base on rebiopsy 
(p=0.004) (Table 16).  
 
Table 16. Associations between MRI and carcinoma location in rebiopsy (Pearson chi-squared test) (study IV). 
 
MRI 
Rebiopsy apex dx mid dx basis dx apex sin mid sin basis sin 
apex dx 0.307      
mid dx  0.430 0.004    
basis dx   0.977    
apex sin    0.584   
mid sin     0.059 0.545 
basis sin      0.409 
dx = right; sin = left       
 
By the time of the analysis 23 patients had already discontinued AS; 19 of these 
were due to reclassification/progression in the first rebiopsy (Gleason score >6 
and/or number of PC positive cores >2) and the remaining 4 were because of 
biochemical progression, i.e. PSADT<3 years. None of the patients discontinued AS 
due to MRI results or anxiety. 	   The only predicting variable for active treatment was higher PSA at 
discontinuation (p=0.002). Appearance of tumour suspicion (Table 17) on T2-W 
MRI (p=0.273) or on ADC maps (p=0.691) could not predict treatment change 
according to the logistic regression analysis (Table 17). The PPV and NPV for MRI 
findings in predicting treatment change were 30% and 73%, and for ADC maps 30% 
and 72%. 
 
Table 17. Logistic regression analysis of overall treatment changes (study IV). 
Variable     p-value   OR (95% Cl) 
Age     0.057   0.9 (0.73-1.01) 
PSA at diagnosis    0.371   0.8 (0.41-1.40) 
PSA density    0.921   1.0 (0.99-1.01) 
% of PC at diagnostic biopsy   0.199   1.8 (0.74-4.28) 
PSADT     0.921   1.0 (0.99-1.01) 
PSA at stopping AS    0.002   1.8 (1.23-2.59) 
MRI/T2     0.273   3.4 (0.38-30.73) 
ADC     0.691   0.6 (0.07-5.86) 	   	  
ADC = apparent diffusion coefficient; OR = odds ratio; PSA = prostate-specific antigen 
Study 
population 
(N=80) 
Gleason score 
at diagnostic 
biopsy 
                      
Cancer positive 
cores at 
diagnostic 
biopsy 
Gleason score 
at rebiopsy 
Cancer 
positive cores 
at rebiopsy 
Discontinue on 
AS 
MRI 
r 
p value 
 
0.000 
1.000 
 
0.109 
0.329 
 
-0.006 
0.530 
 
0.098 
0.739 
 
-0.028 
0.805 
ADC 
r 
p value 
 
-0.041 
0.712 
 
-0.169 
0.131 
 
-0.055 
0.447 
 
-0.089 
0.887 
 
0.021 
0.848 
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Results of RP specimen were available from 22 patients. All PCs in specimens were 
small (median cancer surface 5%; range 1-25%) and prostate confined (<pT3). Four 
patients had a Gleason score of 6, 12 patients Gleason scores of (3+4) and six 
patients Gleason score of (4+3) for PC. Of 22 operated patients, 50% (11) had a 
lesion suggestive of malignancy as indicated by DW-MRI and in eight patients the 
lesion also appeared malignant in the ADC map. No significant association was 
noted between cancer location in RP specimen and MRI. 	  
8.5 Free/total PSA ratios in patients on AS (study V) 
The diagnostic %fPSA value data of 939 PRIAS patients were obtained. Table 18 
presents the characteristics of the study cohort. By the time of the analysis 438 men 
had been on AS for at least a year and these men provided data for the 12 months 
follow-up %fPSA measurements.  
By the time of analysis 656/939 (69.9%) patients of study cohort were still on 
AS, because 283/939 (30.1%) had discontinued. Of these 283, 181 (64.0%) had 
discontinued AS for protocol-based reasons and 102 (36.0%) for non-protocol based 
reasons such as anxiety. The median surveillance was 17.2 (range 0.7-82.7) months. 
The median follow-up period until discontinuation (for all reasons) was 14.7 months 
(range 0.7-82.7) and for protocol-based discontinuation 14.9 (range 4.0-54.8) 
months. Of the discontinued patients, 153 (54.1%) had undergone RP (i.e. robot-
assisted laparoscopic or open retropubic), 32 (11.3%) had EBRT, 40 (14.1%) BT 
and one (0.4%) patient underwent HIFU. 19 (6.7%) patients had changed AS to WW 
and in 38 (13.4%) patients another kind of management option was chosen or 
information about treatment was not available. 
 
 
Table 18. Characteristics of the study patients (study V).  
Variable             All patients (n=939)   No treatment (n=758) Active treatment (n=181)    p value 
Age, yr, median (25-75p)           64.9 (60.0-69.6) 65.2 (60.1-69.8)    64.4 (60.4-68.3)       0.290 
 
Prostate vol, cm3, median (25-75p)   44.0 (34.9-54.0) 44.0 (35.0-55.0)  43.7 (33.5-52.0)    0.176 
 
PSA, ng/mL, median (25-75p)            5.6 (4.5-7.0)  5.6 (4.5-6.8)  5.8 (4.8-7.3)         0.063  
 
%fPSA, median (25-75p)              14.5 (9.7-18.8) 14.7 (10.1-19.7)  13.5 (8.6-18.6)      0.068  
 
PSAD, ng/mL/g, median (25-75p)      0.13 (0.10-0.16)  0.13 (0.10-0.16)    0.14 (0.11-0.17)      0.001*  
 
Clinical stage, no (%)         0.451 
T1c            863 (91.9)  699 (92.2)  164 (90.6)    
T2a-c            76 (8.1)  59 (7.8)   17 (9.4) 
          
 
Biopsy cores median, no (25-75p)     12 (10-12)  12 (10-12)   12 (10-12)               0.004* 
 
Positive biopsy, no (%)             0.050 
 1            649 (69.1)  534 (70.4)   115 (63.5)  
 2            282 (30.0)  216 (28.5)   66 (36.5) 
 NA            8 (0.9)  8 (1.1) 
*Significant result (p<0.05) 
25-75p = 25-75th percentile 
PSA = prostate-specific antigen; fPSA% = free/total PSA ratio (%); PSAD = prostate-specific antigen density 	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First rebiopsy results were available for 595 of the study patients. PC reclassification 
occurred in 144 (24.2%). The predicting variables for adverse first rebiopsy findings 
(i.e. Gleason score >6 and/or >2 PC positive biopsy cores) were the number of 
cancer positive cores (one versus two) at the diagnostic biopsy (p=0.000) and age at 
diagnosis (p=0.002) (Table 19).  
 
 
Table 19. Association of baseline characteristics with rebiopsy progression (study V).   
Baseline characteristics   1-year rebiopsy (n=595)     
    OR (95% Cl)   p value 
 
Age at dg    1.1 (1.02-1.09)   0.002* 
 
PSA     0.96 (0.74-1.25)   0.79 
 
%fPSA    1.0 (0.99-1.04)   0.41 
 
PSAD    1.1 (0.95-1.22)   0.26 
 
Clinical stage       0.17 
 T1c   ref.  
 T2   1.62 (0.81-3.24)   
  
Total Bx cores   0.98 (0.88-1.08)   0.64 
 
Positive Bx cores       0.000* 
 1   ref. 
 2   2.06 (1.38-3.09)   
 
*Significant result (p<0.05) 
PSA = prostate-specific antigen; fPSA% = free/total PSA ratio (%); PSAD = prostate-specific antigen density; OR = odds ratio;  
CI = confidence interval 
 
 
In a multivariate analysis, baseline %fPSA could not predict the probability of 
treatment change, although after a year of AS the difference in median %fPSA 
values between those men still on AS compared to those who had discontinued was 
statistically significant (p=0.031) (Table 20). The probability of discontinuing AS 
was significantly lower in men with a baseline of %fPSA ≥15 and a positive %fPSA 
velocity compared to men with a baseline of %fPSA <15 and a negative %fPSA 
velocity (p=0.001)(Fig.10). 
 
 
 
Table 20. Baseline %fPSA and after 12 months of AS, stratified into subgroups on the basis of treatment change 
(study V). 
 
 
 
 
 
 
AS 
continue/ 
discontinue 
(n=438) 
AS continued 
(n=324) 
 
AS discontinued due to protocol-
based reasons (n=114) 
 
p value 
%fPSA at dg, median (25-75p) 14.4 (8.9-18.5) 13.0 (8.7-17.9) 0.602 
%fPSA after 12 months, 
median (25-75p) 
16.6 (10.7-20.9) 13.1 (10.0-18.5) 0.031* 
*Significant result (p<0.05) 
dg = diagnosis; 
25-75p = 25th and 75th percentiles 
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Figure 10. Treatment-free survival of study patients stratified into subgroups based on %fPSA characteristics 
(study V).  
 
1) %fPSA ≥15 and %fPSA velocity positive 
2) %fPSA ≥15 and %fSA velocity negative 
3) %fPSA <15 and %fPSA velocity positive 
4) %fPSA <15 and %fPSA velocity negative 	  
Statistical differences between groups:  p <0.05; 1 vs. 4  
p ≥0.05; all other comparisons 
 
Cox regression analysis demonstrated an association between PSAD and treatment 
change, as well as an association between the number of PC positive cores at the 
diagnostic biopsy and treatment change due to protocol-based reasons (Table 21). 
Cox regression analysis also revealed that PSAD was the only baseline variable 
predictive for unfavourable RP findings (T3 and/or Gleason score of >6) (Table 22). 
 
Table 21. Association of baseline characteristics with treatment change (protocol-based) over time (study V).  
Baseline characteristics  Treatment change   p value 
    (n=181) 
     HR (95% Cl)   
Age at dg    1.0 (0.97-1.02)     0.81 
 
PSA     1.0 (0.94-1.14)  0.48 
 
%fPSA    0.99 (0.88-1.20)  0.74 
 
PSAD    1.1 (1.01-1.11)  0.013* 
 
Clinical stage      0.39 
 T1c    ref.  
 T2    1.3 (0.74-2.18)   
  
Total Bx cores   1.0 (0.92-1.08)  0.92 
 
Positive Bx cores      0.019* 
 1    ref. 
 2    1.5 (1.07-2.01)   
*Significant result (p<0.05) 
PSA = prostate-specific antigen; fPSA% = free/total PSA ratio (%); PSAD = prostate-specific antigen density;  
HR = hazard ratio 
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Table 22. Association of baseline characteristics and PSA-DT with unfavourable radical prostatectomy findings 
(Cox regression) (study V).   
Baseline characteristics and  Radical prostatectomy 
PSA-DT    (n=53)  
    HR (95% Cl)  p value 
 
Age at diagnosis   1.0 (0.97-1.01)  0.43 
 
PSA     0.9 (0.74-1.06)  0.18 
 
%fPSA    1.0 (0.98-1.06)  0.43 
 
PSAD    3.5 (1.14-5.09)  0.028* 
 
Clinical stage      0.67 
  T1c   ref.  
  T2   0.76 (0.21-2.73)   
  
Total biopsy cores   1.1 (0.72-1.68)  0.84 
 
Positive biopsy cores     0.20 
  1   ref. 
  2   1.1 (0.63-2.12)   
 
 PSADT       0.41 
  Negative or >10 yrs ref.     
  3 to 10 yrs  1.0 (0.48-2.11) 
            <3 yrs   0.6 (0.25-1.43) 
*Significant result (p<0.05) 
HR = hazard ratio; PSA = prostate-specific antigen; fPSA% = free/total PSA ratio (%); PSAD = prostate-specific 
antigen density; PSADT = PSA doubling time 
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9. DISCUSSION 
 
9.1 Short-term outcomes of the PRIAS study (study I) 
 
AS has been proposed to alleviate the problem of overdiagnosis and overtreatment of 
low-risk PCs. Special interest in AS was shown when the ERSPC data on decreasing 
mortality were published (Schröder et al. 2009; Schröder et al. 2012) in tandem with 
the notion of overdiagnosis.  
The study I presents interim data from the largest prospective AS cohort, 
with a good protocol compliance, based on the first 500 PRIAS study inclusions. 
The main outcome parameter was ATFS. The results showed that one out of every 
four patients following a strict surveillance protocol discontinued AS, the ATFS 
value was 73% after 2 years. In the majority of cases, AS was discontinued for 
protocol-based reasons (83%). Adverse rebiopsy findings were an important reason 
for discontinuation of AS, since every fifth patient had adverse characteristics in the 
standard 1-year rebiopsy. PSADT, which was calculated after a year of surveillance, 
was not significantly associated with favourable or unfavourable rebiopsy outcomes. 
The short-term results of this prospective study are valuable in assessing the utility 
of this AS protocol in men with early PC. 
 Recently published results from more mature PRIAS data demonstrated a 
slightly higher ATFS rate of approximately 77% at two years (Bul et al. 2013b). In 
general, results of this study are in accordance with the other AS studies, which have 
reported ATFS rates between 67-86% (van As et al. 2008; Dall'Era et al. 2008; Klotz 
et al. 2010b; Soloway et al. 2010; Tosoian et al. 2011), though this depends on 
patient selection and median follow-up periods. During AS, approximately every 
third PC will be reclassified and such patients have higher risk for disease 
progression. The proportion of men discontinuing surveillance, mainly depends on 
how stringent the inclusion criteria for AS are and how rapidly the clinician is 
willing to initiate active treatment. The more stringent criteria for AS, i.e. biopsies 
with only one or two positive cores with minimal PC will be, the more likely to 
comprise a cohort that remain untreated. Based on the interim results of PRIAS trial 
(I) and other AS studies, it seems obvious, that a considerable number of patients 
discontinue AS during follow-up and this emphasizes the importance of accurate 
staging and grading at diagnosis. If patient selection could be improved, perhaps AS 
follow-up strategies could be simplified. Avoiding or delaying radical treatments is a 
fundamental goal of AS. Therefore, the switching to deferred active treatment during 
surveillance when reclassification or progression of disease occurs, is a relevant part 
of this strategy. 
 In most cases tumour upgrading is probably caused by undersampling at 
diagnostic biopsy, thus subsequently leading to tumour reclassification at rebiopsy 
(Bul et al. 2012a), although true biological progression of PC may also occur. 22% 
of our patients had adverse rebiopsy findings in the 1-year rebiopsy. Results for 
PRIAS data with longer follow-up and larger patient cohort are similar, as 27% of 
men experienced PC reclassification at rebiopsy during surveillance. Other studies 
have reported reclassification rates between 18-55% of cases (Al Otaibi et al. 2008; 
Ross et al. 2010; Adamy et al. 2011; Isharwal et al. 2011; Kotb et al. 2011). In our 
analysis the number of positive biopsy cores at diagnostic biopsy was the only 
parameter that showed a positive association to unfavourable rebiopsy result. The 
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most recent analyses from PRIAS data have demonstrated, that the strongest 
predictor for reclassification is PSAD, in addition to the number of positive biopsy 
cores (Bul et al. 2012a; Bul et al. 2013b). One of the main aims of AS studies is an 
attempt to find those factors that could predict and identify higher risk PCs in AS 
cohorts. With more precise predictors and patient selection it would be possible to 
reduce the number of patients who undergo reclassification of PC and treatment 
change. At present, MRI and novel biomarkers such as isoforms of PSA are under 
very active research in their potential roles as tools in AS protocols. 
 The number of RP specimens in the present study (I) is too low to draw any 
definite conclusions. However, the results of our cohort of deferred RPs are in line 
with those of previously published studies that have evaluated RP outcomes of men 
who would have been eligible for AS (Conti et al. 2009; Kane et al. 2010; Thaxton et 
al. 2010; Drouin et al. 2012;). The rate of tumour upgrading in these studies varied 
between 21-36%, positive surgical margin rates ranged between 14-35% and the 
extracapsular extension rates were between 5-19%. One of the main issues related to 
the AS is the concern of ‘missing the window’ of curability. In comparison to 
immediately treated patients, it would be logical that larger PCs and more 
extracapsular extension could appear in RP specimens after surveillance. Patients 
were directed for deferred active treatment mainly because of increasing PSA values 
or because of an upgrading at rebiopsy. This would make the patient cohort more 
selected than those in a retrospective series, which evaluate RP outcomes of patients 
who would otherwise have been eligible for AS. Several studies have already 
evaluated the oncological outcomes of the RP series compared to immediate 
treatment in men with low-risk PC and in most series no significant differences 
between outcomes have been observed (Warlick et al. 2006; van den Bergh et al. 
2010b; Holmstrom et al. 2010; Dall'Era et al. 2011; Bul et al. 2012c). Recently, RP 
outcomes from the more mature PRIAS data have been published. Those authors 
found that in the majority of cases pathology results of deferred RPs had organ-
confined PC and favourable Gleason gradings. 
 The strengths of this study (I) are its prospective nature and the large patient 
cohort. The PRIAS study has already included more patients than any other 
prospective AS trial. This study also has robust protocol compliance with PRIAS 
and adherence, which is probably due to web-based inclusion and follow-up. The 
limitations of this study are the lack of a randomized control group, which received 
immediate radical treatment after PC diagnosis and a short follow-up period. Based 
on the current analysis, I conclude that no new indications could be found that would 
tighten the existing PRIAS criteria and thereby improve the safety of the AS 
strategy. Moreover, the data of study I emphasizes the importance of prostate 
rebiopsy during AS.    
9.2 QOL during the continuum of PC: the effect of the 
screening process and AS (studies II and III) 
 
Studies II and III both show that short-term changes in health-related QOL appear 
non-substantial during the screening process or during AS, as measured by the 
RAND-36 instrument. In addition, both studies show that the mean HRQL scores are 
comparable to those of the general Finnish population; in patients on AS perhaps 
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even better. This is likely a consequence of selecting those patients for AS who, 
according to a treating clinician, can psychologically cope with it. 
 
9.2.1 Short-term effects of PC screening on HRQL (study III) 
 
Although reduction in mortality from PC is the principal endpoint in the screening 
trials, the effects on QOL are also important. Some concern has been raised about 
the possible negative effects on psychological health and QOL that relate to 
screening process. Our results suggest that population-based PC screening does not 
seem to provoke major effects on participants’ short-term HRQL, as assessed by the 
structured and validated RAND-36 instrument (III). The minor differences in HRQL 
observed between the five phases of PC screening were not significant. The changes 
in HRQL seem to have been temporary as they occurred only at one time point and 
did not persist throughout the screening process. Our results are supported by the 
outcomes of previous studies that concluded PC screening has only little if any 
impact on the psychological health of the participants (Brindle et al. 2006; Awsare et 
al. 2008). Negative emotional impacts may araise, but these do not seem to persist in 
the long-term (Collins et al. 2011). Increased cancer-related anxiety in the short-term 
has been reported, but again, no severe or long-term effects were observed (Wardle 
et al. 1993). One exception may be those screening participants who have pre-
existing anxiety, as they also tend to remain anxious (Essink-Bot et al. 1998). In 
concordance with our results, the Rotterdam section of the ERSPC trial also reported 
minor effects of PC screening on QOL or health-status in the short-term. An 
exception were short-lasting side effects that were related to the prostate biopsy 
(Essink-Bot et al. 1998). This is logical, since TRUS-guided prostate biopsy has 
been associated with discomfort, anxiety and substantial pain in a proportion of men 
(Peyromaure et al. 2002), even to the extent, that some men refused rebiopsy. TRUS 
and biopsy could be considered as a threshold for screening participants as they are 
the most invasive part of PC screening process. However, only a minority of men 
experience elevated distress levels at the time of prostate biopsy or after receiving 
negative results (Macefield et al. 2010). Similarly, a higher serum PSA value, older 
age or a PC positive family history did not predict anxiety in men during a testing 
process for PC (Macefield et al. 2009). Even men with false-positive screening 
results have been reported to view their screening experience as positive (Essink-Bot 
et al. 2003). In contrast, a later study revealed that a proportion of men with a benign 
prostate biopsy result were concerned about PC (Katz et al. 2007). Overall it seems 
that the most significant adverse psychological and QOL effects occur mainly after 
PC diagnosis during the period of different treatments or surveillance strategies. 
 Overall, only a few statistically significant differences were observed 
between different phases of the screening process in this study. The emotional-role 
subscale score decreased following DRE, but it is unclear, if this is the effect of the 
examination itself or if it relates to the awareness of further diagnostic examinations. 
Study participants were aware of their abnormal screening results, but at the time 
their HRQLs were evaluated, they were not aware of the findings of the current 
screening phase. Therefore, these screening phases were thought to be the most 
stressful, but surprisingly HRQL scores turned out to be better in men with an 
abnormal screening finding (PSA≥3), compared to participants with normal PSA 
value. One explanation for this can be, that men with an abnormal PSA result felt 
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relieved by the fact that they were being further examined by the clinician. The 
ordinal regression analysis indicated that a higher PSA was associated with a better 
HRQL except at the DRE phase. However, some studies have shown, that men with 
an elevated PSA value are not able to assess the risk for false-negative or false-
positive results, or risk for PC, as both over- and underestimations are common 
(Frosch et al. 2001; Chan et al. 2003; Katz et al. 2007). 
 Studying five different cohorts at different phases of screening instead of a 
longitudinal cohort moving along each of five phases may be considered as a 
shortcoming of this study. However, this study design was originally chosen to avoid 
bias arising from loss during follow-up, which would likely have occurred, if the 
same study group had been asked to fill in the same questionnaire for up to four 
times at consecutive phases of the screening process. In addition, a large number of 
participants would have been needed, to ensure that a sufficient cohort of study 
participants would have been available in the final phase, due to incomplete 
participation and the relatively low number of men that would be referred and have 
to undergo prostate biopsy. A potential bias could also have resulted from 
participants responding to the questions in the same way out of habit. Our study 
design may increase sampling error, but we found no indication of such as judged by 
the sociodemographic and lifestyle factors of three study samples. A potential bias 
that should be taken into account when interpreting our study results, is the lack of 
comparisons between groups of respondents and non-respondents. 
 
9.2.2 Short-term changes in HRQL during AS (study II) 
 
Some concern has been raised about AS causing a psychological burden on patients 
as they live with untreated PC. Our results (II) contradict this and show that men 
with low-risk PC manage AS well, i.e. AS does not seem to provoke adverse HRQL 
changes in the short-term. The only statistically significant finding was the 
improvement in physical role functioning, but that change was not considered to be 
clinically significant (II). In our study cohort, none of the patients discontinued AS 
due to non-protocol based reasons such as anxiety or distress. In the majority of men, 
the reason for discontinuation was reclassification of PC in the first prostate rebiopsy 
a year after follow-up. These results are in line with the findings of recent studies 
showing that QOL is relatively good in most men on AS, with low levels of anxiety 
and distress, and good psychological and physical wellbeing (van den Bergh et al. 
2009a; van den Bergh et al. 2010a).  
 Psychological factors, such as increased anxiety or distress, may lead to 
discontinuation of AS. In the public mind the term ‘cancer’ is generally conflated 
with a dreaded disease, and a diagnosis of cancer is strongly associated with a 
distressing experience. The diagnosis of PC is also likely to cause many 
psychosocial responses in patients and their family members. Men who consider 
low-risk cancer as a dreaded and life-threatening disease, are probably more suitable 
candidates for immediate curative treatment, as a conservative management option 
such as AS may be difficult for them to accept thus causing more anxiety, distress 
and perhaps reduces their general QOL. Awareness of the untreated cancer may also 
cause undue anxiety during follow-up, resulting in discontinuation of surveillance in 
the absence of objective signs of disease reclassification or progression. Some 
studies have reported nonmedical reasons to be a significant factor, which 
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contributes to discontinuing AS (Choo et al. 2002). In our study cohort of 500 
patients (I), only a minority (17%) of men stopped AS due to psychological factors 
(i.e. increased anxiety/distress) or on request. In a recent update of the PRIAS trial, 
the proportion of patients who switched from AS to deferred treatment because of 
anxiety was 9% (Bul et al. 2013b). Interestingly, none of the patients in the Finnish 
arm of the trial discontinued AS due to anxiety (II). It is remarkable that these 
studies are nonrandomized and participants comprise a highly self-selected cohort. 
This may explain to large extent the low impact of AS on HRQL (II). After PC 
diagnosis, patients are comprehensively informed about the different treatment 
options in the discussions with a clinician and with a specialized PC nurse. Our 
patients (II) also completed their first HRQL questionnaire only after choosing AS as 
their treatment option and thus they were already aware of the good prognosis of 
their disease. This may have further alleviated the anxiety and psychological stress. 
After discussions with the treating urologist and in the opinion of that urologist’s, 
only patients considered able to be able to cope well mentally with the idea of 
‘possibly insignificant PC’ and ‘living with untreated PC’, were actually offered AS 
as their primary treatment choice, making the study cohort highly selected. Thus, it 
may be possible that only those patients with favourable psychological 
characteristics and who are likely to adhere to study protocol are eventually 
included. Perhaps as a result of the multidisciplinary teamwork (a clinician and a PC 
nurse) described in this study and the highly selected group of patients, none of the 
patients in our cohort discontinued due to anxiety (II).  
When properly selecting patients for AS, it is important for a clinician to be 
aware of the possible risk of psychological morbidity in men during AS, as 
psychological symptoms may influence patient’s likelihood to discontinue 
surveillance. The personality of the patients and their behavioural characteristics 
should be considered within a broader perspective, because these may have a 
considerable effect on the psychological burden in the long-term (Blank and Bellizzi 
2006). On some occasions, uncertainty and awareness of the existence of an 
untreated cancer may become too much for a patient to bear, leading to immediate 
radical treatment instead of AS, to prevent continuing or increasing concerns about 
the disease (Patel et al. 2004). The Dutch PRIAS investigators reported that during a 
nine-month period of AS, anxiety and distress levels remain relatively low, but 
patients with a more neurotic personality and lower physical health scores had higher 
anxiety and distress levels (van den Bergh et al. 2009a; van den Bergh et al. 2010a). 
Impaired mental health has also shown to be a predictive factor for poor QOL in 
men on AS (Bellardita et al. 2013).  
Although AS as a management option for low-risk PC is gaining popularity 
currently, only a limited proportion of men who were suitable for this strategy 
eventually choose AS (10-57%) (Cooperberg et al. 2007; Miocinovic et al. 2011). 
The main reason for choosing AS, is the wish to delay the possible physical side 
effects of radical treatments (van Vugt et al. 2012). However, uncertainty related to 
untreated PC and the fear of cancer progression are the main reasons to abandon AS 
as an option (Steginga et al. 2008; Xu et al. 2011). Experiences of friends and family 
members have a significant influence on a patient when he is considering the choice 
of treatment options (Xu et al. 2011). Demographic factors and the extent of 
knowledge about PC may infuence and also contribute to the treatment choice (van 
den Bergh et al. 2012). The clinician has a key role in the choice made as the 
patients are strongly influenced by their treating clinicians with regard to selecting 
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the treatment (Davison and Goldenberg 2011; Xu et al. 2011). A previous study 
suggested that men diagnosed with low-risk PC should obtain improved support and 
patients and their partners should be more involved in the decision-making process 
(Steginga et al. 2008). The active participation of the patient in the treatment 
decision may have a positive effect on that patient´s sense of control. A common 
phenomenon is that patients have difficulties in decision-making and thus decision-
related distress may persist over time. Cancer-specific psychological distress (such 
as fear of recurrence, but not overall anxiety) appears to be related to elevations of 
PSA levels; and this distress also influences treatment pathways. Decision support 
interventions are known to be acceptable to men, they improve patients’ knowledge 
and may reduce decision- and cancer-related distress (Steginga et al. 2008). Every 
person is unique and there is a wide variation in the amount of psychological care 
and support an individual needs (Lintz et al. 2003). It is probable that the importance 
of multidisciplinary teams will be emphasized in supporting men during AS, such as 
when guiding how to cope with higher levels of anxiety and distress. Increased 
education, communication and peer-support groups may also alleviate and improve 
the sense of patient’s control of the situation during AS (Pickles et al. 2007).  
The results of study II indicate that AS does not seem to provoke significant 
short-term QOL disturbances in respect of urinary or erectile function, as assessed 
by the standardized IPSS and IIEF-5 questionnaires. A minor, but statistically 
nonsignificant, increase was noted in the IPSS total score. Urinary, sexual and bowel 
function scores have been shown to decrease due to aging alone during WW and the 
same is expected to occur during AS (Arredondo et al. 2008). Side effects of radical 
treatments may improve even for a long time after treatment, whereas urinary, bowel 
and sexual functions may worsen during AS. A previous retrospective study has 
demonstrated the preferable side effect profile of AS (urinary, bowel or sexual 
function scores) compared with the side effects of radical treatments (Thong et al. 
2010). However, prospective and randomized trials with longer follow-up are needed 
to clarify the true longitudinal changes associated with AS.  
The strengths of study II are its prospective nature and the use of 
standardized, validated questionnaires. Its limitations include the lack of 
randomization and a highly selected patient cohort. A longer follow-up period is 
needed to have longitudinal evidence regarding to HRQL in patients on AS. The 
effects of different treatments for low-risk PC on HRQL should also be compared 
more comprehensively in randomized trials, such as the ProtecT study (Lane et al. 
2010).  
 
9.2.3 Challenges in measuring QOL (studies II and III) 
 
In both of the QOL studies (II and III), the same generic HRQL intrument, RAND-
36 was used. This questionnaire is extensively validated and has been used earlier. A 
challenge in measuring HRQL is in its multidimensional nature, which includes 
physical, mental and social components. Generic, domain- or disease-specific 
questionnaires can be used for QOL studies. The advantage of using generic 
questionnaires, such as RAND-36, is the possibility for comparison across diseases, 
disease stages, treatments and between individuals with and without the condition. A 
drawback of generic questionnaires is the lack of sensitivity and specificity for the 
detection of minor subtle changes in a person´s mental or physical health, which are 
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induced by inter alia PC screening or the AS protocol. Baseline psychological 
factors can continue to be predictive of anxiety and distress long after the screening 
process and during AS. These psychological phenomena may not be measurable by 
using only general HRQL questionnaires. In addition, measuring generic HRQL is 
merely an indirect way of studying possible coincidental emotional reactions that 
have arisen during screening process or during AS. In this study, we did not have 
information on the men's personality traits such as their predisposition to anxiety, or 
their coping strategies. In order to detect possible subtle changes in men´s 
psychological function during the screening process or in AS, more sensitive 
measures that focus on specific symptoms such as anxiety or distress might be useful 
(Avery et al. 2008; Macefield et al. 2010). In addition, another challenge to QOL 
based-studies is the timing of when the questionnaires were given as it has been 
observed that QOL can vary rather rapidly, even while waiting for a PSA result 
(Dale et al. 2005). 
 
9.3 Possible diagnostic and prognostic tools for AS 
(studies IV and V)  
 
9.3.1 DW-MRI in AS (study IV) 
 
One objective of study IV was to evaluate, if DW-MRI interpreted in a routine 
clinical setting by a general uroradiologist, could be used as a diagnostic or 
prognostic tool in AS. A specific aim of the study was to clarify, whether DW-MRI 
findings would correlate with rebiopsy findings and whether treatment change could 
be predicted. Study data revealed only a poor correlation between tumour location 
on MRI and prostate biopsies, and also tumour appearance on MRI could not predict 
either treatment change or rebiopsy findings.  
DW-MRI has been shown to be more sensitive and specific in detecting 
malignant tumours than conventional T2-W MRI (Kim et al. 2007; Afaq et al. 2011; 
Miao et al. 2007). DW-MRI also offers additional information and value in the form 
of ADC maps (Vargas et al. 2011). Only a few studies have shown MRI and ADC 
mapping to be a valuable tool in PC imaging on AS. One of those studies showed 
that ADC values for both benign and cancerous tissue decreased over time in men 
with PC progression in AS, whereas the changes in ADC values were not significant 
in non-progressors (Morgan et al. 2011). Other studies showed that tumour ADC 
values can be potentially differentiated between high-risk and low-risk PC (deSouza 
et al. 2008) and predicted deferred radical treatment (van As et al. 2009). 
Multiparametric MRI i.e. the combination of different MRI modalities (T2 weighted 
imaging combined DW-MRI and/or DCE-MRI and/or MR spectroscopy) may 
further improve the performance of MRI (Turkbey et al. 2011a). The usefulness of 
MRI in patients on AS is currently under active research, and some studies have 
already supported the incorporation of MRI into surveillance protocols (van As et al. 
2009; Fradet et al. 2010; Vargas et al. 2011; Margel et al. 2012). 
Results of the present MRI-study (IV) showed a poor correlation between 
biopsy and MRI findings, especially in the apex. One explanation for this result may 
be, that the biopsies themselves correlated poorly with the respective RP specimen 
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(Gregori et al. 2001; Mayes et al. 2011). Moreover, most of the study patients in our 
PRIAS AS programme (IV) were likely to have a minimal low-grade PC. We found 
that one out of three patients had no cancer on rebiopsy and the majority of men with 
cancer on rebiopsy had small Gleason score 6 PC foci. This finding is in line with 
the results of previous studies, which found that low-grade PCs are a challenge to 
visualize on MRI (Vargas et al. 2011; Guzzo et al. 2012). Although encouraging 
results have been published for the use of MRI during AS (van As et al. 2009; Fradet 
et al. 2010; Vargas et al. 2011; Margel et al. 2012), some studies have failed to show 
such a benefit (Cabrera et al. 2008; Ploussard et al. 2011c; Shukla-Dave et al. 2012). 
Clearly, our results are hampered by the fact that MRIs were evaluated by a general 
radiologist, instead of uroradiologist with a special expertise in interpreting prostate 
MRI findings. It has been shown that the experience of radiologists has a significant 
influence on diagnostic accuracy in interpreting MR images. The number of false 
reports is dependent on the observer and the rate of misinterpretations has been 
found to be significantly higher in a less experienced group of radiologists (Krampla 
et al. 2009). In the present study (IV), the small number of RPs was such that the 
correlation analysis between MRI and RP findings lacked statistical-power. 
Guidelines have recently been introduced for prostate MRI imaging 
including a structured reporting protocol (Barentsz et al. 2012), to improve the 
reproducibility and reliability of MRI. The published guidelines indicate, that the 
current minimal requirements for DW-MRI are b-values of 0, 100, and 800-1000 
s/mm2 (Barentsz et al. 2012). When study (IV) was originally designed, no standard 
technique for performing prostate DW-MRI existed, nor was there any 
recommendation for a structured reporting protocol. The b-values used (300-600 
s/mm2) in study (IV) may not have been optimal, as clearly higher b-values are 
currently recommended for PC detection (Hoeks et al. 2011). It may be that the 
tumours are probably not visible with b-values under 600 s/mm2 (Afaq et al. 2011). 
Another limitation of this study is the use of qualitative (rated as either positive or 
negative) instead of quantitative analysis. Dichotomizing continuous variable (ADC-
values) may have resulted in a loss of power of the analysis, despite the fact that 
currently there is no consensus of the cut-off ADC values for malignant findings for 
the prostate (Kim et al. 2007; Gibbs et al. 2009; Woodfield et al. 2010; Vargas et al. 
2011). Patients in our study had MRI only after one year of follow-up, but not at the 
diagnosis. This can cause some bias in the assessment of MRI as changes during 
surveillance cannot be analysed. However, the rationale to conduct MRI before 
standard 1-year rebiopsy was based on the fact that transrectal prostate biopsy may 
miss a considerable number of tumors, especially tumours that are located apically. 
Another aim of the study was to rule out these tumours during AS (Vis et al. 2000; 
Mazal et al. 2001; Iremashvili et al. 2012). In addition, multiparametric MRI was not 
available in our institution at the time and this may also have contributed to the 
results (Turkbey et al. 2011a). Multiparametric imaging in PC diagnosis would also 
require a specially trained uroradiologist to interpret the MRI images. Such 
uroradiologists will probably not be available in many small-volume centres. The 
absence of endorectal coil and the use of a pelvic coil instead, may be considered as 
a relative shortcoming of the study, although no consensus exists about the use of 
coil type (Dickinson et al. 2011).  
The strengths of this study are the use of modern imaging technology (3T 
MRI), timing of the rebiopsies and the prospective nature of the study. A recent 
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European consensus meeting concluded that 3T MRI is an optimal imaging 
technique (Dickinson et al. 2011) for PC.  
The present study (IV) results indicate that DW-MRI as performed here, did 
not provide any additional prognostic benefit or reliable information to guide the 
treatment of PC patients on AS. Further evaluations by a well-trained uroradiologists 
are essential to assess whether multiparametric MRI prostate imaging will add 
sufficiently to prognostic tools to justify its routine use in a clinical setting. 
 
9.3.2 %fPSA ratio as a prognostic tool on AS (study V) 
 
Although AS is a widely accepted management option for PC, more accurate staging 
and grading at an early stage of PC could further increase the acceptance and uptake 
of this strategy. Although there are a lot of expectations for the utility of MRI as a 
tool in AS programs, novel biomarkers are also needed and they are under ongoing 
urologic research. In the present study (V) we aimed at evaluating if free/total 
%fPSA could serve as a prognostic tool in the AS protocol. The specific aim of the 
study V was to address, whether a %fPSA evaluation at diagnosis and during follow-
up would associate with rebiopsy or RP findings or whether the discontinuation of 
AS could be predicted. Although median %fPSA values were statistically 
significantly different between those men still on AS compared to those who had 
discontinued, the results showed no clinically relevant associations of diagnostic 
%fPSA to guide clinical practice. However, the probability of continuing AS was the 
highest in men with favourable %fPSA characteristics at diagnosis and also during 
surveillance. 
 The %fPSA as a marker in predicting the probability of PC diagnosis is 
widely evaluated (Partin et al. 1996; Catalona et al. 1998). The association between a 
low %fPSA and a clinically significant PC has been demonstrated (Nam et al. 2007), 
in addition to the association between a low %fPSA and a higher grade PC with 
aggressive characteristics (Southwick et al. 1999; Catalona et al. 2000). Only a few 
studies have clarified the role of %fPSA as a prognostic tool in the AS setting. In 
contrast to our results, a few previous studies demonstrated that %fPSA may predict 
adverse histology in rebiopsy (Selvadurai et al. 2013) and the time to deferred 
radical treatment (van As et al. 2008; Selvadurai et al. 2013) in men with low-risk 
PC on AS. In contrast to the PRIAS protocol used in studies (I, II, IV and V), the 
other patient cohorts also included higher risk cancers, i.e. Gleason score 7 (3+4), 
which is likely to increase the statistical power of the analyses for the end-points 
used. The PRIAS patient population represents a rather homogenous cohort, as only 
minimal findings of low-risk PC and maximum Gleason score of 6 are accepted 
criteria. In addition, the definitions for adverse rebiopsy findings and also %fPSA 
cut-off used at follow-up, were all different making it difficult to compare the results 
between studies. Only the 1-year rebiopsy results were predominantly used for the 
analysis in our study due to the limited number of patients available with both 
%fPSA and first rebiopsy results. It is probable that first rebiopsies after the year of 
surveillance are likely to have a high preponderance of misclassification of PC at 
diagnosis instead of true cancer progression. Longer follow-up is, therefore, needed 
to further assess the role of diagnostic %fPSA in this PRIAS patient cohort. The 
multivariate analysis indicated that baseline characteristics that were associated with 
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treatment change due to protocol-based reasons, were PSAD and the number of PC 
positive cores at diagnostic biopsy (study V). This is in line with results from other 
AS cohorts (Kotb et al. 2011; San Francisco et al. 2011) and with the data from a 
recent PRIAS analysis (Bul et al. 2013b), which also support the validity of the 
present analysis. 
Although baseline %fPSA could not predict the treatment change, the median 
%fPSA value after one year of surveillance was significantly higher in men 
continuing AS compared to men who discontinued AS due to protocol-based 
reasons. The difference was particularly significant when %fPSA and %fPSA-
velocity were used as a joined categorical variable in the analysis. The probability to 
continue AS was highest in those patients with a favourable %fPSA at diagnosis and 
during surveillance, i.e. an initial %fPSA of over 15 and a positive %fPSA velocity. 
At present, the literature on the utility of %fPSA-velocity as a prognostic tool in AS 
strategies is scarce. Although the role of PSA-kinetics in general is still unclear and 
its utility in AS strategy has raised some doubts (Iremashvili et al. 2013), to our 
knowledge %fPSA-velocity has not been studied as a predictor of AS outcomes 
before. It may be that longitudinal biomarker measurements have a better predictive 
accuracy than a single baseline value in AS programmes (Ng et al. 2009) and serial 
measurements over time may provide the potential to characterize the tumour more 
accurately than on the basis of a single baseline measurement. Interestingly, recently 
published data suggests that PSA-velocity risk count is independently associated 
with adverse histology in rebiopsy in an AS cohort (Patel et al. 2013). The 
multivariate analysis of our study (V) determined that the baseline variables 
predictive of adverse histology in rebiopsy were the number of PC positive cores at 
diagnostic biopsy and age. Reclassification of disease was more likely to occur in 
men with two cancer positive cores at diagnostic biopsy compared to men who had 
only one positive biopsy core. This finding concords with those data of the recent 
PRIAS interim study (Bul et al. 2013b), and also with the results from other AS 
series (van As et al. 2008; Dall'Era et al. 2008; Klotz et al. 2010b; Tosoian et al. 
2011).  
 Study (V) data could not show any association between %fPSA and RP 
findings and the only predicting variable identified by the multivariate analysis was 
PSAD, which has also been demonstrated previously (Vellekoop et al. 2014). In 
contrast to study V data, few previous studies have shown the association between 
low %fPSA values and significant upgrading of low-grade PC after RP (Visapaa et 
al. 2010). However, the capability of %fPSA in predicting higher stage PC in RP 
(Southwick et al. 1999; Elabbady and Khedr 2006) and also further adverse 
pathology following surgery have been reported (Steuber et al. 2007). The small 
number of RPs done in our series is insufficient to provide the statistical power 
needed for meaningful analysis and therefore results of study V do not allow 
drawing of definite conclusions. Furthermore, a larger AS cohort and longer follow-
up time is needed to clarify this issue more precisely. 	  
9.4 Future perspectives 
 
Several prospective AS studies have been initiated within the past decade to increase 
our knowledge on AS as a management option for low-risk PC. Unfortunately, 
follow-up periods in the majority of AS cohorts are still too short and longer follow-
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up is needed to evaluate proper long-term outcomes and resolve the optimal 
eligibility criteria, the follow-up protocol and any triggers for intervention in AS. At 
present, the PRIAS study is the largest prospective AS trial. However, a lack of 
randomization must be considered as a study weakness. There are a few challenges 
in AS study design regarding the randomization, as the patient cohort needed would 
be very large and would need to have a long follow-up time. It is also probable that 
eventually the differences in survival benefits of radical treatments appear minor 
(Bill-Axelson et al. 2008). In the near future, the results from a randomized ProtecT- 
trial are awaited. That study aims to evaluate the differences between radical 
treatments and AS in low-risk PC, and hopefully it will clarify the assessment of 
mortality and morbidity associated with AS and radical treatment approaches (Lane 
et al. 2010).  
Unless there is a new strategy to prevent the overdiagnosis of low-risk PCs 
implemented, AS is likely to remain as a major management option for insignificant 
PC. The rationale for the AS strategy is obvious, but there are still challenges to 
resolve, e.g. how to distinguish reliably insignificant PCs from aggressive PCs, so 
that the curability of the disease is not missed due to misclassification or true 
progression or a combination of both. A more accurate staging and grading of PC is 
thus needed and research on new biomarkers and imaging techniques, such as 
multiparametric MRI, is essential and will hopefully improve the usefulness of AS in 
routine clinical practice. Targeted biopsies that use MRI have raised interest in focal 
ablation. Treating the dominant PC lesion instead of the whole prostate gland may 
result in sufficient PC control while avoiding the side effects of radical treatments 
(Hou et al. 2009). 
Retrospective studies with longer follow-up have provided evidence that AS 
is a safe management option in men with low-risk PC (Bul et al. 2012b; Godtman et 
al. 2013), but prospective longitudinal series with longer follow-up are warranted to 
validate the accuracy of this interpretation. Currently the inclusion criteria, 
surveillance protocols and the triggers for intervention vary between AS trials. 
Therefore, detailed reporting of the data from these trials is essential as they mature, 
which is the aim of the ongoing PRIAS study. A global AS database with data from 
all the major AS series is currently under consideration to overcome inherent 
challenges in randomized trials on low-risk prostate cancer. Creation of biobanks, 
e.g. the Prostate Active Surveillance Study (PASS), will allow research on the 
genetic and molecular profile of low-risk PC and changes of these characteristics 
during AS (Newcomb et al. 2010). Patients on AS also represent a cohort that 
enables reseach on secondary prevention strategies (Parsons et al. 2009). Finally, 
QOL is a subject for further analysis and requires long-term data to clarify the 
possible long-term effects of AS on anxiety, distress and QOL in general. The 
importance of options and capabilities of multidisciplinary teams in supporting men 
during AS especially needs further evaluation. 
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10. SUMMARY AND CONCLUSIONS 
 
The objectives of the present study were to analyse the feasibility of AS strategy and 
outcomes in the short-term after PC diagnosis. The QOL of men during the first 
steps of the continuum of PC disease, i.e. during the screening and AS was also 
studied. The utility of DW-MRI and free/total PSA ratio, as additional prognostic 
tools in AS were investigated. 
 
The following conclusions of the five studies can be drawn: 
 
I. AS appears to be a feasible strategy to avoid overtreatment in the short-
term in selected men diagnosed with low-risk PC. Active monitoring and 
applying strict criteria of the PRIAS protocol in study I resulted in a 
quarter of the patients discontinuing surveillance after two years. The 
main reason for stopping AS was the adverse findings in the standard 1-
year rebiopsy and biopsy results, and were independent of the PSADT. 
The present short-term analysis, indicated the mortality outcomes remain 
unknown, but the PRIAS-based protocol used in study I seems not to 
have comprised curability. 
 
II. The standardized QOL questionnaires revealed that AS does not seem to 
cause short-term QOL disturbances, when the questionnaires were 
administered to patients after entering AS and who were receiving 
specialized support for their management choice. During the short 
follow-up none of the study patients discontinued due to anxiety or 
distress. The HRQL of patients on AS was significantly better than for 
the general age-stratified Finnish male population.  
 
III. HRQL effects of PC screening, as carried out in the Finnish arm of the 
ERSPC study and assessed by standardized HRQL-questionnaire, appear 
minor and transient in the short-term. The screened participants were also 
found to be comparable to the general population as HRQL scores were 
similar to those of the age-stratified general Finnish male population. 
 
 
IV. DW-MRI data, as interpreted in a routine clinical setting and performed 
in study IV, did not provide additional prognostic benefit in comparison 
with the PSA measurement or with prostate rebiopsies. Localized low-
grade PC is challenging to visualize by DW-MRI and it should be further 
studied. It remains to be seen, if the multiparametric approach of prostate 
MRI and well-trained uroradiologists will add sufficiently to pre-existing 
prognostic tools of AS and induce the routine use of MRI in a clinical 
setting. 
 
V. Diagnostic %fPSA alone could not provide any detectable additional 
prognostic benefit when compared to other predictors already used in AS 
protocols, such as PSA-kinetics. However, %fPSA coupled to %fPSA-
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velocity during AS may aid in predicting the probability for 
discontinuation of AS due to protocol-based reasons and future treatment 
change.  
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13. APPENDICES 	  
The FinnProstate XI Co-ordinators and Trial Centers 
 
Etelä- Pohjanmaa Central Hospital, Seinäjoki: Markku Leskinen 
Etelä-Savo Central Hospital, Mikkeli: Niilo Hendolin, Tapani Liukkonen  
Helsinki University Hospital: Antti Rannikko 
Kuopio University Hospital: Sirpa Aaltomaa 
Kuusankoski District Hospital: Markku Multanen, Markku Onali 
Oulu University Hospital: Pekka Hellström, Erkki Ollikkala  
Päijät-Häme Central Hospital, Lahti: Taina Isotalo  
Tampere University Hospital: Andres Kotsar, Teuvo Tammela 	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Rand-36 health-related quality of life questionnaire 	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IPSS questionnaire   	  	  
1. Kuinka usein teillä on ollut tunne, että rakko ei ole tyhjentynyt täysin virtsaamisen 
jälkeen? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
 
 
2. Kuinka usein teidän on täytynyt virtsata uudelleen ennen kuin edellisestä 
virtsaamisesta on kulunut kaksi tuntia? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
 
 
3. Kuinka usein olette huomannut, että virtsasuihku on katkeillut virtsaamisen aikana? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
 
 
4. Kuinka usein teillä on ollut vaikeuksia pidättää virtsaa virtsaamistarpeen ilmaannuttua? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
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5. Kuinka usein olette huomannut, että virtsasuihku on heikentynyt? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
 
 
 
6. Kuinka usein olette joutunut ponnistelemaan saadaksenne virtsaamisen käyntiin? 
Ei koskaan 
Noin joka 5. kerta 
Noin joka 3. kerta 
Noin joka 2. kerta 
Noin kahtena kertana kolmesta 
Melkein aina 
 
 
7. Kuinka monta kertaa yön aikana olette tavallisimmin joutunut nousemaan virtsalle 
mentyänne illalla nukkumaan ja ennen kuin nousitte aamulla ylös? 
En kertaakaan 
Kerran 
2 kertaa 
3 kertaa 
4 kertaa 
5 kertaa tai useammin 	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Sukupuolielämän häiriöiden kyselykaavake miehille (IIEF-5)
Tämä kyselykaavake on suunniteltu helpottamaan Sinun ja lääkärisi
välistä keskustelua erektiohäiriösi selvittelyssä ja hoidon suunnittelussa.
Valitse ja ympyröi kunkin kysymyksen vastausvaihtoehdoista se, joka
parhaiten kuvaa Sinun tilannettasi viimeisen 6 kuukauden aikana.
Valitse jokaiseen kysymykseen ainoastaan yksi vastaus!
Viimeisen 6 kuukauden aikana:
1. Millaiseksi arvioitte luottamuksenne siihen, että voitte saavuttaa
erektion ja säilyttää sen yhdynnän ajan
1 = Hyvin vähäiseksi
2 = Vähäiseksi
3 = Kohtalaiseksi
4 = Suureksi
5 = Hyvin suureksi
2. Kun Teillä oli seksuaalisen kiihottumisen aikana erektioita, 
kuinka usein ne olivat tarpeeksi kovia yhdyntään?
0 = Ei seksuaalista toimintaa
1 = Ei koskaan tai ei juuri koskaan
2 = Muutaman kerran (harvemmin kuin joka toisella kerralla)
3 = Joskus (noin joka toisella kerralla)
4 = Useimmiten (useammin kuin joka toisella kerralla)
5 = Melkein aina tai aina
3. Kuinka usein pystyitte yhdynnässä ylläpitämään erektion sisään
työntymisen jälkeen?
0 =En yrittänyt yhdyntää
1 = En koskaan tai en juuri koskaan
2 = Muutaman kerran (harvemmin kuin joka toisella kerralla)
3 = Joskus (noin joka toisella kerralla)
4 = Useimmiten (useammin kuin joka toisella kerralla)
5 = Melkein aina tai aina
4. Kuinka vaikeaa Teidän oli säilyttää erektionne yhdynnän
loppuun saakka?
0 = En yrittänyt yhdyntää
1 = Äärimmäisen vaikeaa
2 = Hyvin vaikeaa
3 = Vaikeaa
4 = Hieman vaikeaa
5 = Ei lainkaan vaikeaa
5. Kun yrititte sukupuoliyhdyntää, kuinka usein  saitte siitä tyydytystä?
0 = En yrittänyt yhdyntää
1 = En koskaan tai en juuri koskaan
2 = Muutaman kerran (harvemmin kuin joka toisella kerralla)
3 = Joskus (noin joka toisella kerralla)
4 = Useimmiten (useammin kuin joka toisella kerralla)
5 = Melkein aina tai aina
Yhteispistemäärä:
Alle 22 pistettä viittaa erektiohäiriön olemassaoloon. Keskustelkaa
tilanteesta lääkärinne kanssa, jos haluatte hoitoa erektiohäiriön
hoitamiseksi.
Nimi __________________________________________________________
Sosiaaliturvatunnus ______________________________________________
Päivämäärä _____________________________________________________
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